

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

### ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

The board (the “**Board**”) of directors (the “**Directors**”) of Transcenta Holding Limited (the “**Company**” or “**Transcenta**”, and together with its subsidiaries, the “**Group**”) is pleased to announce the audited consolidated results of the Group for the year ended December 31, 2025 (the “**Reporting Period**”), together with the comparative figures for the year ended December 31, 2024. The consolidated financial statements of the Group for the Reporting Period have been reviewed by the audit committee of the Company (the “**Audit Committee**”) and audited by the Company’s auditors, Ernst & Young (the “**Auditor**”).

In this announcement, “we”, “us” and “our” refer to the Company (as defined above) and where the context otherwise requires, the Group (as defined above). Certain amount and percentage figure included in this announcement have been subject to rounding adjustments, or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding.

#### FINANCIAL HIGHLIGHTS

##### International Financial Reporting Standards (“IFRS”) Measures:

- **Revenue** decreased from RMB11.3 million for the year ended December 31, 2024 to RMB7.4 million for the year ended December 31, 2025, primarily attributable to the decrease in CDMO services.
- **Other income** decreased by RMB8.3 million from RMB23.5 million for the year ended December 31, 2024 to RMB15.2 million for the year ended December 31, 2025, primarily attributable to the decrease in interest income recognized during the year ended December 31, 2025.
- **Other gains and losses** decreased by RMB8.1 million from a loss of RMB20.2 million for the year ended December 31, 2024 to a loss of RMB12.1 million for the year ended December 31, 2025, primarily attributable to decrease in loss on disposal of property, plant and equipment.

- **Research and development expenses** decreased by RMB51.3 million from RMB192.1 million for the year ended December 31, 2024 to RMB140.8 million for the year ended December 31, 2025, primarily attributable to our pipeline advancement and resource prioritization.
- **Administrative and selling expenses** decreased by RMB11.5 million from RMB70.5 million for the year ended December 31, 2024 to RMB59.0 million for the year ended December 31, 2025, primarily attributable to the decrease in personnel cost and office expenses.
- As a result of the above factors, **total comprehensive loss for the year** decreased by RMB96 million from RMB294.3 million for the year ended December 31, 2024 to RMB198.3 million for the year ended December 31, 2025, primarily attributable to our pipeline advancement and resource prioritization.

#### **Non-International Financial Reporting Standards (“Non-IFRS”) Measures:**

- **Revenue** decreased from RMB11.3 million for the year ended December 31, 2024 to RMB7.4 million for the year ended December 31, 2025, primarily attributable to the decrease in CDMO services.
- **Other income** decreased by RMB8.3 million from RMB23.5 million for the year ended December 31, 2024 to RMB15.2 million for the year ended December 31, 2025, primarily attributable to the decrease in interest income recognized during the year ended December 31, 2025.
- **Research and development expenses** excluding the share-based payment expenses decreased by RMB41.9 million from RMB178.1 million for the year ended December 31, 2024 to RMB136.2 million for the year ended December 31, 2025, primarily attributable to our pipeline advancement and resource prioritization.
- **Administrative and selling expenses** excluding the share-based payment expenses decreased by RMB5.1 million from RMB60.5 million for the year ended December 31, 2024 to RMB55.4 million for the year ended December 31, 2025, primarily attributable to decrease in personnel cost.
- **Adjusted loss and total comprehensive loss for the year** excluding share-based payment expenses decreased by RMB80.4 million from RMB270.4 million for the year ended December 31, 2024 to RMB190.0 million for the year ended December 31, 2025, primarily due to decrease in R&D expenses.

## BUSINESS HIGHLIGHTS

### Summary

During the Reporting Period, the Company delivered strong execution across its oncology and non-oncology pipelines, with continued acceleration of clinical development and portfolio advancement.

In oncology, the Company's Claudin18.2-targeting antibody osemitamab (TST001) achieved significant late-stage progress in the treatment of patients with Claudin18.2-expressing locally advanced or metastatic gastric or gastroesophageal junction ("G/GEJ") cancer. Updated efficacy analyses from Cohort G of the Phase I/II TranStar102 study, presented at ASCO in June and ESMO Asia in December, further demonstrated the robust clinical activity of osemitamab in combination with nivolumab and CAPOX as the first-line treatment of patients with G/GEJ cancer. Among 26 patients with high/medium CLDN18.2 expression ( $\geq 40\%$   $\geq 2+$ ) and known PD-L1 CPS, the median progression-free survival reached 16.6 months, with an objective response rate of 68% and a median duration of response of 18.0 months, at a median follow-up of 25.8 months. The Company also obtained regulatory clearances from the U.S. Food and Drug Administration (FDA), China Center for Drug Evaluation (CDE), and South Korea Ministry of Food and Drug Safety for the planned global Phase III trial (TranStar301). In addition, patents relating to osemitamab (TST001) were granted by the China National Intellectual Property Administration, the Federal Service for Intellectual Property of the Russian Federation, and the Intellectual Property Department of Hong Kong, further strengthening the intellectual property position of the program.

The Company continued to advance discussions for the development and commercialization of osemitamab (TST001) with multiple global and regional pharmaceutical companies. Several parties are conducting due-diligence reviews and/or proceeding with term-sheet and contract level negotiations covering global and regional collaboration scopes. The Company has also garnered term sheet-level interest from global and regional investment institutions, with which the Company has been in active discussions to secure funding for the asset. Pending the successful completion of these partnerships or funding within the first half of 2026, the Company expects to initiate the TranStar301 Phase III trial within 2026.

Beyond osemitamab (TST001), the Company also made solid progress advancing its early next-generation oncology pipeline, which includes TST003, TST105, TST013, TST198 and ozekibart. Preclinical data for TST105, the humanized anti-FGFR2b antibody-drug conjugate, were presented at the American Association for Cancer Research (AACR) Annual Meeting in April and demonstrated enhanced anti-tumor activity compared with MMAE-based ADCs in gastric and colorectal cancer models, supporting the continued development of the program. Regarding ozekibart, for which the Company holds exclusive rights to develop and commercialize in Greater China, the Company's partner Inhibrx announced positive Phase II data in chondrosarcoma and plans to file a Biologics License Application (BLA) with the FDA in 2026. Given these positive developments, the Company is currently evaluating the most effective and efficient way to advance ozekibart in Greater China.

The Company also continued to expand and diversify its non-oncology pipeline, advancing TST801, a bifunctional antibody targeting BAFF and APRIL, and TST808, a second generation long-acting anti-APRIL antibody for targeting autoimmune kidney diseases. Further, the Company was pleased to learn that the FDA had qualified in December total hip Bone Marrow Density (BMD) as a validated surrogate endpoint to support clinical trials of investigational therapies for post-menopausal women with osteoporosis at risk for fracture, which allows for more efficient clinical trials, potentially enabling faster approval of new osteoporosis treatments and improving patient access. The Company is evaluating how to utilize this positive development to accelerate the clinical development of blosozumab, an anti-sclerostin antibody, in China.

In parallel, the Company made solid and encouraging progress in partnership discussions relating to the technology transfer of certain proprietary bioprocessing technologies and intellectual property, and successfully entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“**EirGenix**”) (TWSE: 6589) to advance integrated continuous biomanufacturing and expand global access to affordable biologics. The terms of the agreement include substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies, reflecting the long-term value both companies expect to create through this collaboration. This milestone collaboration further strengthens the Company’s technology platform, validates its differentiated capabilities, and enhances its long-term growth and value creation potential. The Company continues to pursue additional such collaborations as a means for additive value creation.

During the reporting period, the Company also completed its first placement of new shares, coming approximately 4 years after its IPO and raising net proceeds of approximately HK\$59.34 million. The proceeds will support accelerated pipeline development and further enhance the Company’s financial strength.

### **Clinical Programs Achievements**

#### ***Osemitamab (TST001, A Humanized ADCC Enhanced Claudin18.2 mAb for Solid Tumors)***

- In March 2025, the Hong Kong patent for Claudin18.2 was granted to the Company by the Intellectual Property Department of Hong Kong.

- In June 2025, the Company presented encouraging updated results from the Cohort-G of an ongoing Phase II trial of osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment for patients with advanced G/GEJ cancer (TranStar102). The findings were showcased in a poster presentation (Abstract #4032) at the 2025 ASCO Annual Meeting in Chicago, IL, U.S. In the 26 patients who have CLDN18.2 expression on at least 40% of the tumor cells with 2+ or 3+ intensity per 14G11 IHC LDT assay and known PDL1 status, the mOS reached 21.7 months and the median progression-free survival (mPFS) was 16.6 months. The confirmed objective response rate (cORR) was 68% with a median duration of response (mDoR) of 18.0 months in this population.
- In December 2025, the Company presented updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102 trial of osemitamab (TST001) plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer at ESMO Asia. The exploratory efficacy analysis indicates that better progression-free survival outcomes in patients with higher CLDN18.2 expression ( $\geq 40\%$   $\geq 2+$ ) compared to lower CLDN18.2 expressors ( $< (40\%, \geq 2+)$ ) in both PD-L1 CPS  $< 1$  and  $\geq 1$  subgroups, which indicated the potential treatment benefit of osemitamab is consistent regardless of PD-L1 expression. This new analysis reinforces the encouraging clinical benefit of the osemitamab triple combination regimen in the ongoing study.

#### **Companion Diagnostic Test (CDx) Progress for Osemitamab (TST001)**

- The Company continued the collaboration with Agilent, a world leader in CDx development. The development of Claudin18.2 companion diagnostics (CDx) has advanced as planned to support the TranStar301 global Phase III pivotal trial of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as the first-line treatment in patients with Claudin18.2 expressing locally advanced or metastatic G/GEJ adenocarcinoma.

#### **Research/Early Development Update**

##### ***TST106 (Bispecific ADC Candidate targeting CLDN18.2 positive solid tumors)***

- TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. CLDN18.2 is a clinically validated tumor antigen in gastric and pancreatic cancers, it is also overexpressed in lung cancer and other solid tumors. Further development toward IND filing has been initiated and is ongoing.

##### ***TST198 (A First-in-class Claudin18.2 Targeting RDC)***

- TST198 is a first-in-class Claudin18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors. RDC offers a potential differentiated approach to address payload resistance in patients pre-exposed to antibody drug conjugates. The company has obtained desired drug targeting and promising anti-tumor activity data for the lead RDC in both in vitro and in vivo studies. Further preclinical testing is ongoing.

***TST786 (A First-in-Class Next Generation Trispecific Antibody Candidate Targeting PD1-VEGF and GREMLIN-1)***

- TST786 is a next generation trispecific antibody candidate targeting PD1, VEGF and GREMLIN-1. GREMLIN-1 is a stromal fibroblast derived regulatory protein and contributes to tumor metastasis and has been negatively associated with overall survival. Currently PD1-VEGF bispecifics have shown promising PFS benefits but OS benefit is to be confirmed. The Company's trispecific antibody has the potential to not only improve PFS benefits but also has a high probability to improve OS benefits by blocking tumor metastasis. It is at preclinical stage.
- In 2025, the lead molecule of the Company has been obtained and preclinical testing is ongoing.

***TST013 (An ADC Candidate Targeting LIV-1, A Tumor Antigen Overexpressed in Multiple Solid Tumors)***

- TST013 is a next generation ADC targeting LIV-1, a clinically validated tumor antigen for breast cancer. LIV-1 is also highly expressed in other solid tumors, including lung cancer, prostate cancer, etc. The ADC molecule combines the site-specific conjugation of TOPO-I inhibitor with an in-house humanized antibody that targets distinct epitope and has prolonged PK. The Company has obtained exciting anti-tumor activity data in in vivo pharmacology studies for the ADC lead molecules and initiated the IND-enabling studies. Compared with the benchmark ADC, TST013 displayed significantly improved anti-tumor activity with a good tolerability profile at clinically relevant doses in animal models.
- The Company has completed further in vivo testing of the lead ADC in PDX mouse models for breast cancer, lung cancer and prostate cancer, and initiated the cell line and process development to support for IND filing.

***TST105 (A Bispecific ADC Candidate Targeting Biomarker Expressing Gastric Cancer and Other Solid Tumors)***

- TST105 is a humanized bispecific antibody-based drug conjugate (ADC) targeting FGFR2b and an undisclosed tumor antigen. FGFR2b is a clinically validated tumor antigen in gastric cancer, it is also overexpressed in lung cancer and other solid tumors. The Company has obtained promising anti-tumor activity data for the lead ADC in in vivo studies. In April 2025, the Company presented the preclinical study results at the AACR Annual Meeting. TST105, with a novel topoisomerase I inhibitor payload utilizing glycosyltransferase mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models. The encouraging data presented at AACR underscore the transformative potential of TST105 in treating cancers with high FGFR2b overexpression. The Company is committed to translating this promising candidate into a transformative therapy for patients globally.

### ***TST801 (A Bifunctional Antibody Fusion Protein for Autoimmune Diseases)***

- TST801 is a first-in-class bifunctional antibody fusion protein of anti-BAFF antibody and TACI receptor. BAFF and APRIL, two ligands for TACI receptor, are involved in regulating B cell activation and differentiation. Dual targeting of BAFF and APRIL is a validated approach for the treatment of several autoimmune diseases, including Systemic Lupus Erythematosus (SLE), Lupus nephritis (LN), IgA nephropathy (IgAN), Generalized myasthenia gravis (gMG), etc. TST801 has the potential of delivering improved efficacy in those diseases as well as other B-cell related autoimmune diseases. We have selected the lead molecule and initiated IND-enabling studies. The Company has completed the evaluation of TST801 versus other competing molecules in a mouse model of human Lupus nephritis (human BAFF overexpressing transgenic mice). TST801 demonstrated best-in-class profile in reducing memory B cells, double stranded DNA (dsDNA), Immunoglobulin A (IgA), Immunoglobulin M (IgM) and Immunoglobulin G (IgG), as well as reducing proteinuria and the kidney damage scores.
- The Company has completed the PK/PD study in non-human primates, and the final lead molecule was selected for the process development and IND-enabling studies.

### ***TST808 (A Humanized Antibody Neutralizing APRIL, A Validated Key Target Regulating B/Plasma Cell Proliferation and Survival)***

- TST808 is a humanized antibody neutralizing APRIL, a validated key target regulating B/plasma cell proliferation and survival. TST808 has improved properties in blocking B cell proliferation and signalling. It was engineered to achieve a longer half-life as well. TST808 has the potential of treating multiple autoimmune renal disorders including IgAN. The Company has obtained lead molecules and initiated IND-enabling studies. The Company has engineered a second generation bi-paratopic antibody and is under preclinical evaluation.
- The Company has completed the PK/PD study in non-human primates, and the final lead molecule was selected for the cell line development.

### ***TST008 (A Bi-specific Antibody for MASP-2 and BAFF for Autoimmune Diseases)***

- TST008 is a first-in-class bispecific antibody dual targeting MASP-2 and BAFF. TST008 has both effects on B cell and lectin complement pathway, which providing the potential of delivering better efficacy to disease affected by both pathways, e.g. IgAN, SLE, LN, etc. As at the date of this report, it is at preclinical stage.

## Business Development Achievements

- The Company has continued the clinical trial collaboration with BMS for the osemitamab (TST001), checkpoint inhibitor and chemotherapy combination in the TranStar102 trial in China and in the TranStar101 trial in the U.S.
- The Company has advanced the collaboration with Agilent for our Claudin18.2 specific IHC CDx Assay to support the TranStar301 global Phase III pivotal trial of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy.
- For osemitamab (TST001), the Company is engaged in active discussions with potential partners to support global and regional development and commercialization and has received multiple term sheets and contract level proposals, with negotiations on going.
- The Company is currently in active discussions on partnerships and collaborative opportunities for the Company's pipeline assets to leverage global expertise and resources of potential partners for development and commercialization. The Company is also evaluating strategic deal structures, including the formation of Companies ("NewCo") to advance preclinical and clinical-stage assets with external funding, reducing risk for the parent company while enabling focused and efficient asset development, to accelerate time to market and maximize asset value.
- On December 29, 2025, the Company together with its wholly-owned subsidiary, HJB (Hangzhou) Co., Ltd\* (杭州奕安濟世生物藥業有限公司) ("**HJB Hangzhou**") (collectively, the "**Licensors**"), entered into strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (TWSE: 6589), a global biopharmaceutical development and manufacturing company. Under the agreement, Transcenta will be eligible to receive substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of Transcenta's Highly Intensified Continuous Bioprocessing (HiCB) platform.
- The Company has strengthened the alliance with companies specialized in siRNA drug substance synthesis, providing CDMO services in siRNA formulation development and F&F.
- The Company's in-house cell culture media ExcelPro CHO are being evaluated for performance against market standards for fedbatch and perfusion processes by multiple external partners, including several global leading companies of CHO cell culture media business. This provides opportunities for potential collaboration of global commercialization of ExcelPro CHO media.

## **CMC & CDMO Updates**

### ***Platform and technology development***

- The Company continued to improve the in-house cell line expression system and is on track to make it available for the development of the internal programs as well as licensing to CDMO clients and industry partners.
- The Company established perfusion media for perfusion process. The Company also established basal and feed media for fed-batch process. Those media are ready for commercialization.
- The Company established ADC and RDC cold conjugation development services. The Company's conjugation process and quality analysis platform empowering development of innovative XDC drugs.

### ***CDMO business***

- The Company has expanded its services in siRNA drug product development and increased its exposure to international markets.
- The Company has extended its services to clients in need of drug products in lyophilization dosage form.
- The Company has continued its efforts in engaging new customers for such services.

## **MANAGEMENT DISCUSSION AND ANALYSIS**

### **OVERVIEW**

Transcenta is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with global commercial potential. Supported by a seasoned and international executive leadership team, with particular research and clinical development experience, the Company is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders.

The Company has established a multi-region development strategy designed to enable efficient global registration and commercialization. The Company's lead asset, osemitamab (TST001), is a best-in-class anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. Osemitamab (TST001) has received regulatory clearances from the U.S. FDA, China CDE, and South Korea MFDS to initiate a global Phase III trial evaluating osemitamab (TST001) in combination with a checkpoint inhibitor and chemotherapy as a first-line treatment for Claudin18.2-expressing locally advanced or metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinomas. To support this pivotal study, the Company has developed a proprietary Claudin18.2 antibody for companion diagnostic assay development, strengthening its precision medicine approach and commercial readiness.


Beyond osemitamab (TST001), the Company’s proprietary antibody discovery platform also enables the rapid generation of first-in-class and best-in-class therapeutic candidates, while its comprehensive CMC infrastructure supports seamless advancement from discovery through late-stage clinical development and commercialization. Complementing this, the Company’s advanced translational science platform drives biomarker discovery to support precision medicine development, significantly improving clinical success probabilities and accelerating value realization.

The Company’s HiCB™ manufacturing platform delivers high-quality biologics at meaningfully lower production costs, providing a strong competitive advantage in scalability and margins. Leveraging its end-to-end CMC capabilities, the Company also offers select CDMO services to external partners, generating recurring revenue that enhances operational sustainability.

The Company continues to execute its global growth strategy through strategic collaborations with leading international and domestic biopharmaceutical companies and academic institutions, spanning R&D, manufacturing, and commercialization. In parallel, the Company actively explores innovative transaction structures, including NewCo and asset-level partnerships, to accelerate market entry, optimize capital efficiency, and maximize asset value. Together, these initiatives strengthen global rights management, enhance financial resilience, and expand long-term commercial opportunities across its pipeline.

## Our Product Pipeline

The Company has established a diversified and differentiated pipeline of more than one dozen molecules in oncology, bone disorders, autoimmune diseases, nephrology, and other disorders. All but one of its antibody candidates were generated in-house by its antibody discovery platform covering validated, partially validated, and novel biological pathways; one pipeline candidate, blosozumab (TST002), was acquired through in-licensing. The following chart summarizes the drug candidates that are currently under development globally across various therapeutic areas as of the date of this report:



---

Source: Company

Abbreviations: PD-L1=Programmed death-ligand 1; TGF $\beta$ =Transforming growth factor beta; MASP-2=Mannan-binding lectin serine protease 2; IND=Investigational new drug; FIC=First-in-class; HPV=Human Papillomavirus; NSCLC=Non-small cell lung cancer; SLE=Systemic lupus erythematosus; LN=Lupus nephritis; TMA=Thrombotic microangiopathy; IgA nephropathy=Immunoglobulin A nephropathy; Mono=Monotherapy; Combo=Combination; Chemo=Chemotherapy; DR5=Death Receptor 5.

- (1) Solid tumors in the “Indications” column include all tumor types other than hematologic malignancies. The particular tumor types as indications for each product depends on the mechanism of action of the corresponding drug candidate and emerging or established preclinical/clinical evidence. See the subsections headed “Clinical Development Plan” for each of our drug candidates in “Business” section of the Prospectus for the specific tumor types targeted for clinical development.
- (2) Global in the “Clinical trial region” column represents Asia (including China), North America, South America, Europe and Oceania.

## BUSINESS REVIEW

The Company has established a diversified and differentiated pipeline of more than one dozen molecules in oncology, bone disorders, nephrology and other disorders. In particular, the Company is proud to have developed its four best-in-class molecules, TST001, TST002, TST004, and TST808, and its six first-in-class molecules, TST106, TST198, TST003, TST786, TST801, and TST008. During 2025, the Company made significant progress with its pipeline assets in both oncology and non-oncology therapeutic areas and achieved multiple clinical and preclinical milestones that are listed as follows:

### Oncology Program

The Company’s oncology pipeline includes multiple innovative and differentiated biologic molecules targeting major cancer pathways. Several drug candidates, including osemitamab (TST001), TST003, and TST013, are designed to achieve anti-tumor activities with different mechanisms that are potentially synergistic with each other for indications with high unmet medical needs. The Company’s key oncology candidates include:

- Osemitamab (TST001), the Company’s lead asset, is a potential best-in-class and differentiated antibody targeting Claudin18.2, a validated tumor associated antigen in several solid tumors, including but not limited to gastric and gastroesophageal cancer, pancreatic cancer and lung cancer. Approvals to launch a global Phase III registration trial (TranStar301) to develop osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as the first-line treatment for Claudin18.2 expressing G/GEJ adenocarcinomas have been received from the U.S. FDA, China CDE and South Korea MFDS. Further explorations include other Claudin18.2 expressing tumors in addition to G/GEJ cancer.
- TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. The bispecific antibody is designed to force the antibody to only bind to dual expressing tumor cells but not to CLDN18.2 expressing normal gastric epithelial cells and thus improve safety and efficacy in the targeting population.)
- TST198 is a first-in-class Claudin18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors.

- TST003 is a first-in-class humanized monoclonal antibody targeting GREMLIN-1, which blocks GREM1 signaling in the tumor microenvironment resulting in inhibition of tumor cell differentiation and growth and is currently being explored in solid tumors including CRC, CRPC etc.
- TST786 is a first-in-class next generation trispecific antibody candidate targeting PD1-VEGF and GREMLIN-1.
- TST013 is a next generation ADC targeting LIV-1, a clinically validated target antigen, a candidate at preclinical stage with potential targeting breast cancer and other tumor types.
- TST105 is a bispecific ADC candidate targeting FGFR2b and an undisclosed tumor antigen at preclinical stage for biomarker expressing gastric cancer, lung cancer and other solid tumors.

The Company's broad portfolio also offers opportunities to cover additional unmet medical needs through combinations: for example, TST003 is highly synergistic with osemitamab (TST001) potentially enhancing the Claudin18.2 franchise through proprietary combinations.

### **Osemitamab (TST001) (A Humanized ADCC-enhanced anti-Claudin 18.2 mAb for Solid Tumors)**

Osemitamab (TST001), the Company's lead asset, is a potential best-in-class and ADCC enhanced humanized antibody specifically targeting Claudin18.2 with high-affinity. Claudin18.2 is overexpressed in multiple tumor types, including G/GEJ cancer, pancreatic ductal adenocarcinoma (PDAC) and lung cancer. The Company's strategy is to lead the next wave of innovation by developing osemitamab (TST001) combination with the latest standard of care (i.e., chemotherapy + checkpoint inhibitor), delivering more effective treatment to patients with Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC and lung cancer.

In the first-line Claudin18.2 positive G/GEJ cancer, the combination of Claudin18.2 targeting antibody with chemotherapy has been validated by a competing molecule as an effective treatment option in two global Phase III trials. The competing molecule benefits around 38% of G/GEJ cancer, based on the data in its clinical trials. Osemitamab (TST001) is a second generation Claudin18.2 targeting antibody designed to have more potent anti-tumor activities than the competing molecule. It has higher binding affinity and more potent ADCC (antibody-dependent cellular cytotoxicity) than the competing molecule. ADCC accounts for the direct killing of cancer cells by the anti-Claudin18.2 antibody. Transcenta's preliminary clinical data indicated that osemitamab (TST001) had the potential to benefit a broader patient population (~55% of G/GEJ cancer). The Company's strategy in the first-line advanced or metastatic G/GEJ cancer is to offer patients the best-in-class next wave innovation with osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy for patients with Claudin18.2 expressing G/GEJ cancer.

The Company has made significant progress in 2025 in advancing the clinical development for osemitamab (TST001), which includes:

## ***Recent Product Developments and Milestones***

- In March 2025, the Hong Kong patent for Claudin18.2 was granted to the Company by the Intellectual Property Department of Hong Kong.
- In June 2025, the Company presented encouraging updated results from the Cohort-G of an ongoing Phase II trial of osemitamab (TST001) plus Nivolumab and CAPOX as the first-line treatment for patients with advanced G/GEJ cancer (TranStar102). The findings were showcased in a poster presentation (Abstract #4032) at the 2025 ASCO Annual Meeting in Chicago, IL, U.S. In the 26 patients who have CLDN18.2 expression on at least 40% of the tumor cells with 2+ or 3+ intensity per 14G11 IHC LDT assay and PDL1 known, the mOS reached 21.7 months and the median progression-free survival (mPFS) was 16.6 months. The confirmed objective response rate (cORR) was 68% with a median duration of response (mDoR) of 16.5 months in this population.
- In December 2025, the Company presented updated efficacy analysis of Cohort G by CLDN18.2 and PD-L1 expression from the phase I/II Transtar102 trial of osemitamab (TST001) plus nivolumab and CAPOX in first-line Gastric/Gastroesophageal Junction (G/GEJ) cancer at ESMO Asia. The exploratory efficacy analysis indicates that better progression-free survival outcomes in patients with higher CLDN18.2 expression compared to lower CLDN18.2 expressors in both PD-L1 CPS<1 and  $\geq 1$  subgroups, which indicated the potential treatment benefit of osemitamab (TST001) is consistent regardless of PD-L1 expression. This new analysis reinforces the encouraging clinical benefit of the osemitamab (TST001) triple combination regimen in the ongoing study.

## **CDx Progress for Osemitamab (TST001)**

### ***Recent Product Developments and Milestones***

- The Company continued the collaboration with Agilent, a world leader in CDx development. The development of Claudin18.2 companion diagnostics (CDx) has advanced as planned to support the TranStar301 global Phase III pivotal trial of osemitamab (TST001) in combination with checkpoint inhibitor and chemotherapy as the first-line treatment in patients with Claudin18.2 expressing locally advanced or metastatic G/GEJ adenocarcinoma.

## **TST003 (A First-in-Class Humanized Anti-GREMLIN-1 Antibody)**

TST003 is a first-in-class and high affinity humanized monoclonal antibody targeting GREMLIN-1, a regulatory protein that is highly expressed by stromal cells and tumor cells in diverse human carcinomas, especially in colon cancer, prostate cancer, gastric cancer, lung cancer, esophageal cancer, pancreatic ductal adenocarcinoma and breast cancer. It is currently tested in a global FIH trial at multiple clinical centers in the U.S. and China. Dose escalation as monotherapy has been completed. TST003 has demonstrated good safety and tolerability, and dose proportional PK profiles were observed.

### **TST106 (Bispecific ADC Candidate targeting CLDN18.2 positive solid tumors)**

- TST106 is a humanized bispecific antibody-based drug conjugate (ADC) targeting CLDN18.2 and an undisclosed tumor antigen expressed in multiple tumor types. CLDN18.2 is a clinically validated tumor antigen in gastric and pancreatic cancers, it is also overexpressed in lung cancer and other solid tumors. Further development towards IND filing has been initiated and is ongoing.

### **TST198 (A First-in-class Claudin18.2 Targeting RDC)**

- TST198 is a first-in-class Claudin18.2 targeting RDC optimized with specific tumor targeting to address unmet needs in solid tumors. RDC offers a potential differentiated approach to address payload resistance in patients pre-exposed to antibody drug conjugates. The company has obtained desired drug targeting and promising anti-tumor activity data for the lead RDC in both in vitro and in vivo studies. Further preclinical testing is on-going.

### **TST786 (A First-in-Class Next Generation Trispecific Antibody Candidate Targeting PD1-VEGF and GREMLIN-1)**

TST786 is a next generation trispecific antibody candidate targeting PD1-VEGF and GREMLIN-1. GREMLIN-1 is a stromal fibroblast regulatory protein and contributes to metastasis and has been negatively associated with overall survival. Currently PD1-VEGF bispecifics have shown promising PFS benefits but OS benefit is to be confirmed. The Company's trispecific ab has the potential to not only improve PFS benefits but also has a high probability to improve OS benefits by blocking tumor metastasis. It is at preclinical stage.

#### ***Recent Product Developments and Milestones***

- In 2025, the lead molecule of the Company has been obtained and preclinical testing is ongoing.

### **TST013 (An ADC Candidate Targeting LIV-1, A Tumor Antigen Overexpressed in Multiple Solid Tumors)**

TST013 is a next generation ADC targeting LIV-1, a clinically validated tumor antigen for breast cancer. LIV-1 is also highly expressed in other solid tumors including lung cancer, prostate cancer, etc. The ADC molecule combines the site-specific conjugation of TOPO-I inhibitor, with an in-house humanized antibody that targets distinct epitope and has prolonged PK. The Company has obtained exciting anti-tumor activity data in in vivo pharmacology study for the ADC lead molecules. Compared with the benchmark ADC, TST013 displayed significantly improved anti-tumor activity with a good tolerability profile at clinically relevant doses in animal models. As at the date of this report, it is at preclinical stage. The Company has also observed significant preclinical activities in lung cancer.

#### ***Recent Product Developments and Milestones***

- The Company has completed further in vivo testing of the lead ADC in PDX mouse models for breast cancer, lung cancer and prostate cancer, and initiated the cell line and process development.

## **TST105 (A Bispecific ADC Candidate Targeting Biomarker Expressing Gastric Cancer and Other Solid Tumors)**

TST105 is a humanized bispecific antibody-based drug conjugate (ADC) targeting FGFR2b and an undisclosed tumor antigen, FGFR2b is a validated tumor antigen in gastric cancer, it is also overexpressed in lung cancer and other solid tumors. The Company is currently developing the bispecific ADC to improve therapeutic window. As at the date of this report, it is at preclinical stage.

### ***Recent Product Developments and Milestones***

- In April 2025, the Company presented the preclinical study results of TST105 at the AACR Annual Meeting. TST105, with a novel topoisomerase I inhibitor payload utilizing glycosyltransferase mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models. The encouraging data presented at AACR underscore the transformative potential of TST105 in treating cancers with high FGFR2b overexpression. The Company is committed to translating this promising candidate into a transformative therapy for patients globally.

### **Non-oncology Program**

The Company's highly differentiated non-oncology pipelines target bone and kidney diseases (blosozumab (TST002), TST004, TST008, TST801, and TST808) that have large patient population and high unmet medical needs. The Company has focused on indication expansion with huge market potentials and aim to form partnerships to accelerate product development.

The Company has been developing blosozumab (TST002), a Phase II stage agent targeting bone disorders as a lead asset. To further expand its current pipeline in autoimmune diseases, the Company is developing TST801, a first-in-class bi-functional antibody. This molecule also has the potential for the treatment of IgA nephropathy and other autoimmune diseases, such as SLE, a progressive disease affecting over three million people worldwide with early onset (age 18-44) and limited treatment options to slow down or stop the organ damages caused by the disease.

## **Blosozumab (TST002) (A Humanized Sclerostin mAb for Osteoporosis)**

Blosozumab (TST002), is a humanized monoclonal antibody with neutralizing activity against sclerostin for which the Company inlicensed the Greater China rights from Eli Lilly. Eli Lilly had completed Phase II trial with blosozumab in postmenopausal women in the United States and Japan. The data had shown that blosozumab can induce significant dose-dependent increases in spine, femoral neck, and total hip bone mineral density (BMD) as compared with placebo. In these studies, in the highest dose group, blosozumab treatment increased mean BMD by 17.7% at the spine, and 6.2% at the total hip from baseline after 12 months. The Company obtained encouraging data from 32 Chinese patients treated with a single dose of blosozumab (TST002) and followed for 85 days, including safety, bone formation and resorption markers and BMD data. After a single dose of blosozumab (TST002) up to 1,200 mg, the average increase of lumbar spine BMD at day 85 (D85) ranged from 3.52% to 6.20% and total hip BMD from 1.30% to 2.24% across dose cohorts. The safety, efficacy and PK/PD results of this study are consistent with the clinical data in the U.S. patients. The Company has received Phase II CTP from CDE.

## **TST004 (A Humanized MASP-2 mAb Candidate for IgAN)**

TST004, one of the Company's key products, is a humanized mAb targeting mannan-binding lectin serine protease 2 (MASP-2) designed to prevent inflammation and tissue damage mediated by lectin pathway complement activation. It can be potentially applied to multiple MASP-2-dependent complement mediated diseases, including IgAN, a highly prevalent chronic kidney disease globally. As at the date of this report, it is at the Phase I stage.

## **TST801 (A Bifunctional Antibody Fusion Protein for Autoimmune Diseases)**

TST801 is a first-in-class bifunctional antibody fusion protein of anti-BAFF antibody and TACI receptor. BAFF and APRIL, two ligands for TACI receptor, are involved in regulating B cell activation and differentiation. Dual targeting of BAFF and APRIL is a validated approach for the treatment of several autoimmune diseases including SLE, LN, IgAN, gMG, pSS, etc. TST801 has the potential of delivering better efficacy for the treatment of those diseases and potentially other B-cell related autoimmune diseases. The Company has selected the lead molecule and initiated IND-enabling studies. The Company has completed the evaluation of TST801 versus other competing molecules in a mouse model of human Lupus nephritis (human BAFF overexpressing transgenic mice). TST801 demonstrated best-in-class profile in reducing memory B cells, and dsDNA, IgA, IgM and IgG as well as reducing proteinuria and kidney damage scores. As at the date of this report, it is at preclinical stage.

## ***Recent Product Developments and Milestones***

- The Company has completed the PK/PD study in non-human primates, and the final lead molecule was selected for the process development and IND-enabling studies.

## **TST808 (A Humanized Antibody Neutralizing APRIL, A Validated Key Target Regulating B/plasma Cell Proliferation and Survival)**

TST808 is a humanized antibody neutralizing APRIL, a validated key target regulating B/plasma cell proliferation and survival. TST808 has improved properties in blocking B cell proliferation and signalling. It was engineered to achieve a longer half-life as well. TST808 has the potential to treat multiple autoimmune renal disorders including IgAN. The Company has obtained the lead molecules and initiated IND-enabling studies. The Company has engineered a second generation bi-paratopic antibody which is under preclinical evaluation. As at the date of this report, it is at preclinical stage.

### ***Recent Product Developments and Milestones***

- The Company has completed the PK/PD study in non-human primates, and the final lead molecule was selected for the cell line development.

## **TST008 (A Bi-specific Antibody for MASP-2 and BAFF for Autoimmune Diseases)**

TST008 is a first-in-class bispecific antibody dual targeting MASP-2 and BAFF. TST008 has both effects on B cell and lectin complement pathway, which providing the potential of delivering better efficacy to disease affected by both pathways, e.g. IgAN, SLE, LN, etc. As at the date of this report, it is at preclinical stage.

**Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “Listing Rules”):** The Company cannot guarantee that it will be able to develop, or ultimately market, any of the above drug candidates successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

### **Research and Early Development Efforts**

The Company is optimising its follow-on pipeline molecules using existing technology. The Company is also employing new technologies to explore new targets to enrich its pipeline by developing the next generation of molecules. Additionally, the Company is developing antibody based targeted radioligand therapy by leveraging its antibody engineering and conjugation technologies for improving tumor/normal tissue targeting and therapeutic index. This approach could offer a new modality for multiple targets and address potential limitations of ADC due to payload resistance.

### **Strategic Partnership to Advance Pipeline**

Partnerships and collaborations are the key for maximizing the clinical and commercial potential of our assets. We have established clinical trial collaboration with BMS for osetitamab (TST001), in-licensed blosozumab (TST002) rights in the Greater China with Eli Lilly & Company, and are codeveloping TST004 in China with Alebund Pharmaceuticals. Additionally, we have established multiple research collaborations, including one with an MNC for one of our pipeline molecules and several with companies for different ADC platforms. We also established multiple translational research collaborations with prominent academic institutions including Dana-Farber Cancer Institute and John Hopkins University.

Details of our existing partnerships are shown below.

### ***Osemitamab (TST001)***

The Company aims to develop osemitamab (TST001) as the global cornerstone treatment in Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC, and lung cancer.

In 2022, the Company established a global clinical trial collaboration with Bristol Meyers Squibb (BMS) to evaluate the combination of osemitamab (TST001) with Opdivo® (nivolumab), a global approved anti-PD-1 therapy in the first-line G/GEJ cancer, for the treatment of patients with unresectable locally advanced or metastatic Claudin18.2 expressing G/GEJ cancer. The Company has continued the clinical trial collaboration with BMS.

The Company has been discussing with multiple MNCs and other strategic collaborators on the potential global collaboration of osemitamab (TST001) for Claudin18.2 positive gastric cancer and other solid tumors. With validation of Claudin18.2 target by competing molecule in G/GEJ cancer, the Company believes osemitamab (TST001) will offer a more efficacious treatment for a broader patient population with Claudin18.2 positive G/GEJ cancer through the triple combination, that is, the combination of osemitamab (TST001), the targeted therapy, with the checkpoint inhibitor, and the first-line standard chemotherapy. The global Phase III trial (TranStar301) is designed to generate clinical evidence to support global regulatory approvals.

The Company has advanced its collaboration with Agilent for its Claudin18.2 specific CDx Assay, which is ready to be used for patient selection in our global Phase III study (TranStar301).

The Company is actively engaged in discussion with global to support development and commercialization and has received multiple term sheets and contract level proposals, with negotiations on going.

### ***Blosozumab (TST002)***

In 2019, the Company entered an exclusive and royalty bearing license agreement with Eli Lilly for LY-2541546 (blosozumab), LY-3108653 and LY-2950913 (each a “**Licensed Compound**”). The Company gained exclusive rights to develop, use or commercialize and manufacture the Licensed Compound in the Greater China regions including the PRC, Hong Kong, Macau and Taiwan.

The Company completed technology transfer, established manufacturing process for blosozumab (TST002), and GMP production for clinical use and all the additional preclinical studies required for IND application in China. The Company received IND Clearance from CDE for a Phase II study to validate efficacy and tolerability, and to generate necessary clinical data to support a Phase III study.

The Company has been actively discussing with multiple domestic pharmaceutical companies for the potential collaboration on the development and commercialization of blosozumab (TST002) in the Greater China. The Company is encouraged by the FDA’s approval of total hip bone mineral density (BMD) as a surrogate endpoint in osteoporosis and is evaluating how to leverage this regulatory development to accelerate the clinical development of blosozumab in China.

## **TST004**

The Company collaborates with Shanghai Alebund Pharmaceuticals Limited (“**Alebund Pharmaceuticals**”) after establishing an equity joint venture registered under the law of PRC in 2020 to carry out pre-clinical research and conduct clinical trials in the Greater China region. Currently, the Company has completed GMP material productions, *in vitro/in vivo* product characterization studies, non-GLP tox studies, GLP tox studies and pharmacology studies.

IND clearance has been obtained from FDA. The Company is in discussions for potential global collaboration with multiple companies including MNCs on TST004.

### **Translational Research Collaborations**

The Company also entered multiple research collaborations with prominent academic institutions around the world, including the Dana-Farber Cancer Institute of Harvard Medical School, John Hopkins University, Beijing Cancer Hospital, Shanghai Pulmonary Hospital, Zhongshan Hospital, Zhongshan University, and Shanghai Jiao Tong University. The research collaborations covered osemitamab (TST001), TST003 and TST005.

The Company also established strategic collaborations with multiple technology platform companies to explore different modalities for innovative targets, including multiple ADC platforms. These research collaborations further enhanced our global leading position in Claudin18.2 targeted combination therapies and strengthened our oncology programs.

### **Technology Partnership & Advancement**

- On December 29, 2025, the Company together with its wholly-owned subsidiary, HJB (Hangzhou) Co., Ltd\* (杭州奕安濟世生物藥業有限公司) (“**HJB Hangzhou**”) (collectively, the “**Licensor**”), entered into strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (TWSE: 6589), a global biopharmaceutical development and manufacturing company. Under the agreement, the Company will be eligible to receive substantial upfront and milestone payments, as well as future royalty payments associated with the commercial use of Transcenta’s Highly Intensified Continuous Bioprocessing (HiCB) platform.
- The Company’s in-house cell culture media ExcelPro CHO are being evaluated for performance against market standards for fedbatch and perfusion processes by multiple external partners including several global leading companies of CHO cell culture media business. This provides opportunities for potential collaboration of global commercialization of ExcelPro CHO media.
- The Company has strengthened its alliance with companies specialized in siRNA drug substance synthesis, providing CDMO services in siRNA formulation development and F&F.

## **CMC & CDMO Updates**

### ***Technology Out-licensing***

On December 29, 2025, The Company has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix (TWSE: 6589) pursuant to which the Company will grant EirGenix a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform. The Company has since received the upfront payment and is eligible to receive further milestone payments, as well as future royalty payments, while EirGenix will adopt the HiCB platform to support its biologics development programs, manufacturing operations and CDMO services. The collaboration underscores the value of the HiCB platform in enhancing process efficiency, product consistency and cost competitiveness compared with conventional fed-batch manufacturing processes.

### ***Platform and Technology Development Advancement***

The Company has made significant investment and progress in protein expression system, cell culture media development, bioprocessing technology, analytical technology, and expanding its capabilities into ADC and lyophilization drug product development.

- The Company continued to improve our in-house cell line expression system and are on track to make it available for the development of the internal programs as well as licensing to CDMO clients and industry partners.
- The Company established perfusion media for perfusion process, it also established basal and feed media for fed-batch process. Those media are ready for commercialization.

### ***CDMO Business***

- The Company established perfusion media for perfusion process, it also established basal and feed media for fed-batch process. Those media are ready for commercialization.
- The Company has completed CMC packages in support of clients' IND filings. The Company has expanded its services in siRNA drug product development and increased its exposure to international markets. The Company is supporting siRNA projects in formulation development and drug product fill finish as well as analytical methods development.
- The Company has expanded its services for clients who need drug products in lyophilization dosage form.
- The Company has continued its efforts and engaged new customers for such services.

## **EVENTS AFTER THE REPORTING PERIOD**

- The Company received RMB10 million before withholding tax upfront payment of technology out-licensing of HiCB;
- The Company received RMB43 million new credit line and withdrew new bank loan of RMB13 million;
- The Company is in the contract negotiation for investment proposal from a major strategic investor;
- The Company is in contract negotiation for a product out-licensing partnership;
- The Company has received a new term sheet for a China rights partnership for a major product candidate;
- The Company presented its RDC technology platform, which enables the use of engineered antibody as ligand for RDC development, at the 2026 XDC Conference.

## **FUTURE OUTLOOK**

Looking forward, the Company will advance its development in accordance with four core strategic initiatives to foster sustainable growth and long-term value creation, with clear objectives and actionable plans for the current year as follows:

- The Company is actively working to secure a minimum of US\$100 million in financing throughout the current fiscal year, laying a solid capital foundation for the implementation of its strategic plans and sustained operational development.
- The Company will continue extensive business development and technology collaboration initiatives, leveraging strategic partnerships to broaden financing channels and attract additional funding to support its innovative development and business expansion.
- The Company will concentrate its research and development efforts on the osemitamab (TST001) and blosozumab (TST002) core pipeline projects, while proactively driving business development and strategic cooperation for other pipeline assets to accelerate the advancement and value realization of all pipeline programs.
- The Company will continue to prioritize enhancing operational efficiency, implementing stringent cost control and expense management measures, optimizing resource allocation, and promoting refined operations to ensure the sustainable and healthy development of the business.

The Company expects to advance multiple key pipeline molecule programs and continue to strive to establish collaboration on its leading assets as well as other pipeline molecules. The Company also plans to further advance its technology platform and enhance its out-licensing for new source of revenue. A detailed breakdown of expected developments for the year 2026 is as follows:

## **Clinical Developments**

### ***Osemitamab (TST001)***

- The Company plans to continue to advance its global pivotal trial (TranStar301) of osemitamab (TST001) for first-line G/GEJ cancer patients with Claudin18.2 overexpression. The Company anticipates to initiate TranStar301 Phase III trial in 2026.
- The Company will continue exploring several Claudin18.2 expressing advanced solid tumors other than G/GEJ cancer, as well as early-stage G/GEJ cancer.
- The Company plans to submit the manuscript of study TST001-1002 to the target journal.

### ***Blosozumab (TST002)***

- The Company plans to initiate Phase IIb study to enable dose selection for pivotal trial.

### ***TST003***

- The Company will continue the TST003 Phase I trial to obtain safety, pharmacokinetic and pharmacodynamic data.
- The Company will expand the sample size to conduct exploratory studies in colorectal cancer (CRC) and castration resistant prostate cancer (CRPC).

The company continued to focus on forming partnerships and leveraging external resources for further development of earlier stage assets including TST198, TST786, TST013, TST106, TST801 and TST808.

## **Potential Partnerships**

- The Company expects that the potential collaboration with potential partners will move its lead asset osemitamab (TST001) into a global Phase III trial in the first line CLDN18.2 positive G/GEJ cancer, the critical first step in establishing osemitamab (TST001) as the cornerstone treatment in Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC and lung cancer.
- The Company will continue partnership discussions for our clinical assets blosozumab (TST002), TST003, TST004, and pre-clinical assets including oncology assets TST198, TST106 and TST013, as well as non-oncology assets TST008, TST801 and TST808 to maximize the value of the assets.
- The Company expects to secure additional technology licensing deals for its HiCB technology platform.

## **CMC and Technology Developments**

- The Company aims to strengthen its marketing initiatives for the HiCB continuous technology platform, cell culture media products, and development services to attract industry partners for technology licensing and media business collaborations.
- The Company plans to fully develop in-house cell line expression system and be ready for internal programs and out-licensing to industry partners.
- The Company will continue to strengthen RNA drug product development and manufacture ability.
- The Company will continue to strengthen and expand BD activities globally to increase select service contracts from both China and U.S. clients.
- The Company plans to increase its competitiveness by improving operational efficiency, reducing cost, improving quality, expanding new capabilities.

The Company is accelerating the advancement of its pipeline while actively pursuing high-impact strategic collaborations to further strengthen its global development capabilities. By continuously enhancing its products and technology platforms, the Company is driving greater operational efficiency and meaningful cost optimization. Anchored by a strong global vision and strategy, the Company is well positioned to unlock the full potential of its portfolio and deliver sustained, long-term value growth.

## **Outlook Beyond 2026**

The Company plans to continue expanding and advancing its pipeline while actively exploring strategic partnerships to accelerate global development and maximize the commercial value of our assets. At the same time, the Company will continue to generate sustainable profits from our business, supported by its leading technology, high quality standards, and cost efficiency. Guided by a global vision from the outset, the Company remains committed to enhancing patient benefits and creating additional value across its product portfolio. The Company believes these efforts will unlock the full potential of its portfolio and deliver long-term value for its shareholders, customers, and patients.

## FINANCIAL REVIEW

### Year Ended December 31, 2025 Compared to Year Ended December 31, 2024

	Year ended December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
<b>Revenue</b>	7,435	11,261
Cost of sales	<u>(5,714)</u>	<u>(7,258)</u>
<b>Gross profit</b>	1,721	4,003
Other income	15,248	23,499
Other gains and losses, net	(12,063)	(20,238)
Research and development expenses	(140,821)	(192,055)
Administrative and selling expenses	(58,990)	(70,513)
Impairment losses under expected credit loss model	(2,643)	(11,831)
Impairment losses/(reversal of impairment losses) on contract costs	32	(10,155)
Finance costs	(6,481)	(13,283)
Share of profit of a joint venture	<u>22</u>	<u>31</u>
<b>Loss before tax</b>	(203,975)	(290,542)
Income tax credit	<u>250</u>	<u>250</u>
Loss for the year	<u><u>(203,725)</u></u>	<u><u>(290,292)</u></u>
Other comprehensive income/(loss) for the year		
<i>Item that may be reclassified subsequently to profit or loss:</i>		
Exchange differences arising on translation of a foreign operation	<u>5,456</u>	<u>(4,030)</u>
Total comprehensive loss for the year	<u><u>(198,269)</u></u>	<u><u>(294,322)</u></u>
<b>Non-IFRS measure<sup>(Note 1)</sup>:</b>		
Add: Adjusted for share-based compensation expenses	<u>8,262</u>	<u>23,931</u>
Adjusted loss and total comprehensive loss for the year	<u><u>(190,007)</u></u>	<u><u>(270,391)</u></u>

<sup>1</sup> See section below headed “FINANCIAL INFORMATION – Non-IFRS Measure” for the details of the non-IFRS measure adjustments.

## Selected Data from Statement of Financial Position

AS AT DECEMBER 31, 2025

	At December 31,	
	2025	2024
	RMB'000	RMB'000
Non-current assets	870,165	920,783
Current assets	54,668	279,494
<b>Total assets</b>	<b>924,833</b>	<b>1,200,277</b>
Current liabilities	214,414	342,507
Non-current liabilities	92,326	106,134
<b>Total liabilities</b>	<b>306,740</b>	<b>448,641</b>
<b>Net current liabilities</b>	<b>(159,746)</b>	<b>(63,013)</b>

### 1. Revenue

The Group provides CDMO services and research and development services. CDMO services stands as an integrated platform to support the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients and formulation development and dosage drug product manufacturing, for preclinical, clinical trials, new drug application, and commercial supply of chemical drugs as well as wide spectrum development from early to late stage. The research and development services are mainly for investigational new drug enabling studies based on customers' needs.

The Group primarily earns revenues by providing CDMO services and research and development services to its customers through fee-for-service (“FFS”) contracts. Contract duration is generally a few months to five years. Under FFS method, the contracts usually have multiple deliverable units, which are generally in the form of technical laboratory reports and/or samples, each with individual selling price specified within the contract. The Group identifies each deliverable unit as a separate performance obligation, and recognizes FFS revenue of contractual elements at the point in time upon finalization, delivery and acceptance of the deliverable units.

The Group's service contracts normally include payment schedules which require stage payments over the service period once certain specified milestones are reached. The Group requires certain customers to provide upfront deposits ranging from 10% to 50% of total contract sum as part of its credit risk management policies. This will give rise to contract liabilities at the start of a contract until the deliverable units have been delivered and accepted by customers. The typical credit term is 30 to 90 days upon meeting specified delivery milestones.

Disaggregated revenue information:

	<b>Year ended December 31,</b>	
	<b>2025</b>	<b>2024</b>
	<b><i>RMB'000</i></b>	<b><i>RMB'000</i></b>
CDMO services	<b>6,376</b>	9,024
Research and development services	<b>1,059</b>	2,237
	<b><u>7,435</u></b>	<b><u>11,261</u></b>

**Transaction price allocated to the remaining performance obligation for contracts with customers**

The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at December 31, 2025 and the expected timing of recognising revenue are as follows:

	<b>CDMO services <i>RMB'000</i></b>	<b>Research and development services <i>RMB'000</i></b>
Within one year	<b>2,867</b>	1,187
More than one year	<b>1,466</b>	33,019
	<b><u>4,333</u></b>	<b><u>34,206</u></b>

The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at December 31, 2024 and the expected timing of recognising revenue are as follows:

	<b>CDMO services <i>RMB'000</i></b>	<b>Research and development services <i>RMB'000</i></b>
Within one year	4,457	–
More than one year	853	–
	<b><u>5,310</u></b>	<b><u>–</u></b>

## 2. *Other Income*

Other income consists of bank interest income and government grants. The grants related to income were granted by the PRC local government authorities to group entities as incentives for the Group's research and development activities, and were recognised in profit or loss upon the compliance of the Group with the conditions attached to the grants and the government acknowledged acceptance. The grants related to assets were released to the profit or loss over the expected useful lives of the relevant asset by equal annual instalments.

For the year ended December 31, 2025, other income of our Group decrease by RMB8.3 million from RMB23.5 million for the year ended December 31, 2024 to RMB15.2 million. The decrease was primarily due to the decrease in interest income we recognized during the year ended December 31, 2025.

## 3. *Other Gains and Losses, Net*

Our other net gains and losses decreased from losses of RMB20.2 million for the year ended December 31, 2024 to losses of RMB12.1 million for the Reporting Period. The changes were primarily due to decrease in loss on disposal of property, plant and equipment.

## 4. *Research and Development Expenses*

Research and development expenses primarily consist of pre-clinical expenses including testing fee and pre-clinical trial expenses, staff cost for our research and development personnel, clinical expenses including testing fee and clinical trial expenses, materials consumed for research and development of our drug candidates, depreciation and amortization expenses and others. The research and development expenses decreased by 26.7% from RMB192.1 million for the year ended December 31, 2024 to RMB140.8 million for the year ended December 31, 2025, primarily due to our key pipeline advancement and resource reprioritization.

The following table sets forth the components of the Group's research and development expenses for the year indicated.

	Year ended December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
Contracting costs	27,736	42,487
Staff costs	61,797	94,196
Materials consumed	2,935	1,028
Depreciation and amortization expenses	38,984	41,707
Others	9,369	12,637
<b>Total</b>	<b>140,821</b>	<b>192,055</b>

## 5. *Administrative and Selling Expenses*

Our administrative and selling expenses decreased by 16.3% from RMB70.5 million for the year ended December 31, 2024 to RMB59 million for the year ended December 31, 2025, primarily due to the decrease in personnel cost and office expenses.

Our administrative and selling expenses primarily consist of personnel cost, travel, depreciation and amortization and others. Our administrative expenses consist primarily of salaries and related benefits costs for our administrative personnel, professional fees for services provided by professional institutions, depreciation and amortization expenses, office expenses for our daily operation, traveling and transportation expenses, and others.

The following table sets forth the components of the Group's selling and administrative expenses for the year indicated.

	Year ended December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
Salaries and related benefits costs	26,762	32,996
Professional fees	17,065	15,209
Depreciation and amortization expenses	4,567	6,874
Office expenses	6,858	9,758
Traveling and transportation expenses	1,301	1,738
Others	2,437	3,938
	<u>58,990</u>	<u>70,513</u>

## 6. Trade and other receivables

	At December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
Trade receivables	31,851	31,376
Less: Allowance for credit losses	(15,674)	(13,031)
Trade receivables, net of allowance for credit losses	<u>16,177</u>	<u>18,345</u>
Interest receivables	–	3,949
Prepayments for:		
Research and development services	2,467	4,570
Legal and professional services	1,912	1,830
Purchase of raw materials	<u>293</u>	<u>1,128</u>
	<u>4,672</u>	<u>7,528</u>
Other receivables		
Refundable rental deposits	496	1,419
Others	204	595
Less: Allowance for credit losses	–	(275)
Others, net of allowance for credit losses	<u>700</u>	<u>1,739</u>
	<u>21,549</u>	<u>31,561</u>
Analyzed as:		
Non-current	181	454
Current	<u>21,368</u>	<u>31,107</u>
	<u>21,549</u>	<u>31,561</u>

The Group normally grants a credit period of 30-90 days or a particular period agreed with customers effective from the date when the services have been completed and accepted by customers.

## 7. Trade and other payables

	At December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
Trade payables	<b>67,068</b>	83,143
Accrued research and development expenses	<b>18,591</b>	11,558
Other payables:		
Purchase of property, plant and equipment	<b>5,989</b>	10,698
Legal and professional fee	<b>6,247</b>	2,149
Others	<b>1,182</b>	691
Loans from a related party	<b>2,021</b>	–
Interest payables	<b>95</b>	187
Other tax payables	<b>1,348</b>	1,418
Accrued staff costs and benefits	<b>4,074</b>	4,085
	<hr/>	<hr/>
	<b>106,615</b>	113,929
	<hr/> <hr/>	<hr/> <hr/>

The average credit period on purchases of goods and services of the Group is 30-90 days.

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Year ended December 31, 2025

	<i>Notes</i>	<b>2025</b> <b>RMB'000</b>	2024 RMB'000
REVENUE	4	7,435	11,261
Cost of sales		<u>(5,714)</u>	<u>(7,258)</u>
Gross profit		1,721	4,003
Other income		15,248	23,499
Other gains and losses, net	5	(12,063)	(20,238)
Research and development expenses		(140,821)	(192,055)
Administrative and selling expenses		(58,990)	(70,513)
Impairment losses under expected credit loss model	8	(2,643)	(11,831)
Impairment losses/(reversal of impairment losses) on contract costs		32	(10,155)
Finance costs		(6,481)	(13,283)
Share of profit of a joint venture		<u>22</u>	<u>31</u>
LOSS BEFORE TAX		(203,975)	(290,542)
Income tax credit	6	<u>250</u>	<u>250</u>
LOSS FOR THE YEAR		<u><b>(203,725)</b></u>	<u><b>(290,292)</b></u>
OTHER COMPREHENSIVE INCOME/(LOSS)			
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:			
Exchange differences on translation of a foreign operation		<u>5,456</u>	<u>(4,030)</u>
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX		<u><b>5,456</b></u>	<u><b>(4,030)</b></u>
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		<u><b>(198,269)</b></u>	<u><b>(294,322)</b></u>
Loss for the year attributable to:			
Owners of the Company		<u><b>(203,725)</b></u>	<u><b>(290,292)</b></u>
Total comprehensive loss attributable to:			
Owners of the Company		<u><b>(198,269)</b></u>	<u><b>(294,322)</b></u>
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY			
– Basic and diluted (RMB)	7	<u><b>(0.49)</b></u>	<u><b>(0.72)</b></u>

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at December 31, 2025

	<i>Notes</i>	<b>2025</b> <b>RMB'000</b>	2024 <b>RMB'000</b>
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment		<b>275,592</b>	321,101
Right-of-use assets		<b>20,210</b>	23,206
Goodwill		<b>471,901</b>	471,901
Other Intangible assets		<b>95,667</b>	95,752
Investments in a joint venture		<b>1,315</b>	1,293
Deposits paid for acquisition of property, plant and equipment		<b>128</b>	1,938
Value-added-tax (“VAT”) recoverable		<b>4,891</b>	4,858
Other receivables	8	<b>181</b>	454
Pledged bank deposits		<b>280</b>	280
Total non-current assets		<b>870,165</b>	920,783
<b>CURRENT ASSETS</b>			
Inventories		<b>14,018</b>	16,620
Trade and other receivables	8	<b>21,368</b>	31,107
Contract costs		<b>3,729</b>	2,132
VAT recoverable		<b>1,406</b>	2,512
Pledged/restricted bank deposits		<b>4</b>	57,700
Cash and cash equivalents		<b>14,143</b>	169,423
Total current assets		<b>54,668</b>	279,494
<b>CURRENT LIABILITIES</b>			
Trade and other payables	9	<b>106,615</b>	113,929
Contract liabilities		<b>574</b>	547
Interest-bearing bank borrowings		<b>102,890</b>	217,090
Lease liabilities		<b>3,935</b>	2,541
Deferred income		<b>400</b>	8,400
Total current liabilities		<b>214,414</b>	342,507
NET CURRENT LIABILITIES		<b>(159,746)</b>	(63,013)
TOTAL ASSETS LESS CURRENT LIABILITIES		<b>710,419</b>	857,770

	<i>Notes</i>	<b>2025</b> <b><i>RMB'000</i></b>	2024 <i>RMB'000</i>
<b>NON-CURRENT LIABILITIES</b>			
Interest-bearing bank borrowings		<b>4,900</b>	16,050
Lease liabilities		<b>12,518</b>	14,926
Deferred income		<b>50,300</b>	50,300
Deferred tax liabilities		<b>24,608</b>	24,858
		<hr/>	<hr/>
Total non-current liabilities		<b>92,326</b>	106,134
		<hr/>	<hr/>
Net assets		<b>618,093</b>	751,636
		<hr/> <hr/>	<hr/> <hr/>
<b>EQUITY</b>			
Share capital		<b>295</b>	284
Treasury shares		<b>(2,461)</b>	(2,371)
Reserves		<b>620,259</b>	753,723
		<hr/>	<hr/>
Total equity		<b>618,093</b>	751,636
		<hr/> <hr/>	<hr/> <hr/>

## NOTES

### 1. GENERAL INFORMATION

Transcenta Holding Limited (the “Company”) was incorporated in the British Virgin Islands as an exempted company with limited liability on 20 August 2010, and re-domiciled to the Cayman Islands on 26 March 2021 as an exempted company with limited liability under the laws of Cayman Islands. On 29 September 2021, the Company’s shares became listed on the Main Board of The Stock Exchange of Hong Kong Limited. The address of the registered office of the Company is 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands and the principal place in Hong Kong of business is located at Room 1928, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

The Company is an investment holding company. The Company and its subsidiaries (collectively referred to as the “Group”) is an integrated biopharma platform that brings drug candidates from the discovery stage to the commercial stage, spanning discovery, research, development, manufacturing and commercialization.

### 2. APPLICATION OF AMENDMENTS TO IFRS ACCOUNTING STANDARDS

The Group has adopted amendments to IAS 21 *Lack of Exchangeability* for the first time for the current year’s financial statements. The Group has not early adopted any other standard or amendment that has been issued but is not yet effective.

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted in and the functional currencies of overseas subsidiaries and a joint venture for translation into the Group’s presentation currency were exchangeable, the amendments did not have any impact on the Group’s financial statements.

In addition, the International Accounting Standards Board has issued amendments to Illustrative Examples on IFRS 7, IFRS 18, IAS 1, IAS 8, IAS 36 and IAS 37 *Disclosures about Uncertainties in the Financial Statements*, which added illustrative examples in the corresponding IFRS Accounting Standards. These examples reflect existing requirements in the corresponding IFRS Accounting Standards to report the effects of uncertainties in the financial statements using climate-related examples. Therefore, the amendments do not have an effective date or transitional provisions. The Group has assessed and concluded that the amendments did not have any impact on the Group’s financial statements.

### ISSUED BUT NOT YET EFFECTIVE IFRS ACCOUNTING STANDARDS

The Group has not applied the following new and amended IFRS Accounting Standards that have been issued but are not yet effective, in these financial statements. The Group intends to apply these new and amended IFRS Accounting Standards, if applicable, when they become effective.

IFRS 18	<i>Presentation and Disclosure in Financial Statements</i> <sup>2</sup>
IFRS 19 and its amendments	<i>Subsidiaries without Public Accountability: Disclosures</i> <sup>2</sup>
Amendments to IFRS 9 and IFRS 7	<i>Amendments to the Classification and Measurement of Financial Instruments</i> <sup>1</sup>
Amendments to IFRS 9 and IFRS 7	<i>Contracts Referencing Nature-dependent Electricity</i> <sup>1</sup>
Amendments to IFRS 10 and IAS 28	<i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i> <sup>3</sup>
Amendments to IAS 21	<i>Translation to a Hyperinflationary Presentation Currency</i> <sup>2</sup>
<i>Annual improvement to IFRS Accounting Standards – Volume 11</i>	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7 <sup>1</sup>

<sup>1</sup> Effective for annual periods beginning on or after 1 January 2026

<sup>2</sup> Effective for annual/reporting periods beginning on or after 1 January 2027

<sup>3</sup> No mandatory effective date yet determined but available for adoption

Further information about those IFRS Accounting Standards that are expected to be applicable to the Group is described below.

IFRS 18 replaces IAS 1 *Presentation of Financial Statements*. While a number of sections have been brought forward from IAS 1 with limited changes, IFRS 18 introduces new requirements for presentation within profit or loss, including specified totals and subtotals. Entities are required to classify all income and expenses within the statement of profit or loss into one of the five categories: operating, investing, financing, income taxes and discontinued operations and to present two new defined subtotals. It also requires disclosures about management-defined performance measures in a single note and introduces enhanced requirements on the grouping (aggregation and disaggregation) and the location of information in both the primary financial statements and the notes. Some requirements previously included in IAS 1 are moved to IAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*, which is renamed as IAS 8 *Basis of Preparation of Financial Statements*. As a consequence of the issuance of IFRS 18, limited, but widely applicable, amendments are made to IAS 7 *Statement of Cash Flows*, IAS 33 *Earnings per Share* and IAS 34 *Interim Financial Reporting*. In addition, there are minor consequential amendments to other IFRS Accounting Standards. IFRS 18 and the consequential amendments to other IFRS Accounting Standards are effective for annual periods beginning on or after 1 January 2027 with earlier application permitted. Retrospective application is required. The Group is currently analysing the new requirements and assessing the impact of IFRS 18 on the presentation and disclosure of the Group's financial statements.

Except for IFRS 18, the directors of the Company anticipate that the other new and amended IFRS Accounting Standards are not expected to have a material impact on the Group's financial performance and financial position in the year of initial application.

### 3. OPERATING SEGMENT INFORMATION

#### Segment information

For the purpose of resource allocation and performance assessment, the key management of the entities and business comprising the Group, being the chief operating decision maker, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment and no further analysis of this single segment is presented.

#### Geographical information

##### (a) Revenue from external customers

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Chinese mainland	6,627	10,138
United States of America	808	970
Others	—	153
	<hr/>	<hr/>
Total	<b>7,435</b>	<b>11,261</b>
	<hr/> <hr/>	<hr/> <hr/>

**(b) Non-current assets**

The Group's non-current assets are substantially located in the PRC.

**Information about major customers**

Revenue from customers individually contributing 10% or more of the total revenue of the Group during the corresponding years is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Customer A	2,365	2,809
Customer B	1,227	1,983
Customer C	808	1,887
Customer D	754	–

**4. REVENUE**

An analysis of revenue is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
<i>Revenue from contracts with customers</i>		
CDMO services	6,376	9,024
Research and development services	1,059	2,237
Total	<u>7,435</u>	<u>11,261</u>

**Revenue from contracts with customers**

**(a) Disaggregated revenue information**

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
<b>Geographical markets</b>		
Chinese mainland	6,627	10,138
United States of America	808	970
Others	–	153
Total	<u>7,435</u>	<u>11,261</u>
<b>Timing of revenue recognition</b>		
At a point in time	<u>7,435</u>	<u>11,261</u>

The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Revenue recognised that was included in contract liabilities at the beginning of the reporting period:		
CDMO services	<u>340</u>	<u>342</u>

**(b) Performance obligations**

Information about the Group's performance obligations is summarised below:

The Group provides CDMO services and research and development services. CDMO services stands as an integrated platform to support the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients and formulation development and dosage drug product manufacturing, for preclinical, clinical trials, new drug application, and commercial supply of chemical drugs as well as wide spectrum development from early to late stage. The research and development services are mainly for investigational new drug enabling studies based on customers' needs.

The Group primarily earns revenues by providing CDMO services and research and development services to its customers through fee-for-service ("FFS") contracts. Contract duration is generally a few months to five years. Under FFS method, the contracts usually have multiple deliverable units, which are generally in the form of technical laboratory reports and/or samples, each with individual selling price specified within the contract. The Group identifies each deliverable unit as a separate performance obligation, and recognizes FFS revenue of contractual elements at the point in time upon finalization, delivery and acceptance of the deliverable units.

The Group's service contracts normally include payment schedules which require stage payments over the service period once certain specified milestones are reached. The Group requires certain customers to provide upfront deposits ranging from 10% to 50% of total contract sum as part of its credit risk management policies. This will give rise to contract liabilities at the start of a contract until the deliverable units have been delivered and accepted by the customer.

The amounts of transaction prices allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at 31 December are as follows:

	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
Amounts expected to be recognised as revenue:		
Within one year	<b>4,054</b>	4,457
After one year	<b>34,485</b>	853
	<b>38,539</b>	5,310

The amounts disclosed above do not include variable consideration.

**5. OTHER GAINS AND LOSSES, NET**

	<b>2025</b> <b>RMB'000</b>	2024 <i>RMB'000</i>
Foreign exchange differences, net	<b>(5,615)</b>	3,995
Compensation loss for contract termination related to the purchase of property, plant and equipment	<b>(3,082)</b>	–
Loss on disposal of property, plant and equipment	<b>(3,138)</b>	(25,202)
Gain on disposal of right-of-use assets	–	969
Others	<b>(228)</b>	–
	<b>(12,063)</b>	(20,238)

## 6. INCOME TAX

The Company was incorporated in the BVI and re-domiciled to the Cayman Islands and is exempted from income tax.

Hong Kong Profits Tax is calculated at 16.5% (2024: 16.5%) on the estimated assessable profit.

Under the Law of the People's Republic of China on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the Group's PRC subsidiaries is 25%.

On 18 December 2023, HJB (Hangzhou) Co., Ltd. (杭州奕安濟世生物藥業有限公司) qualified as a High and New Tech Enterprise recognised by the Ministry of Science and Technology and enjoys a preferential tax rate of 15% for a period of three years starting from 2023.

On 6 November 2023, Suzhou Transcenta Therapeutics Co., Ltd. (蘇州創勝醫藥集團有限公司) qualified as a High and New Tech Enterprise recognised by the Ministry of Science and Technology and enjoys a preferential tax rate of 15% for a period of three years starting from 2023.

Certain subsidiaries of the Company were small and low-profit enterprises, and in accordance with the Announcement on the Preferential Income Tax Policies for Small and Micro Enterprises and Individual Industrial and Commercial Households (Announcement No. 12 2023 of the Ministry of Finance and the State Taxation Administration), from 1 January 2023 to 31 December 2027, the annual taxable income of a small and low-profit enterprise that is not more than RMB1 million shall be included in its taxable income at the reduced rate of 25%, with the applicable enterprise income tax rate of 20%.

	<b>2025</b> <b>RMB'000</b>	2024 <b>RMB'000</b>
Current	–	–
Deferred	<u>250</u>	<u>250</u>
Total tax credit	<u><b>250</b></u>	<u>250</u>

A reconciliation of the tax credit applicable to loss before tax at the statutory tax rate for the jurisdiction in which the Company and its subsidiaries are domiciled and/or operate to the tax expense at the effective tax rate is as follows:

	<b>2025</b> <b>RMB'000</b>	2024 <b>RMB'000</b>
Loss before tax	<u><b>(203,975)</b></u>	<u>(290,542)</u>
Income tax expense calculated at 25%	<b>(50,994)</b>	(72,635)
Effect of different tax rates of subsidiaries operating in other jurisdictions and enacted by local authority	<b>14,429</b>	37,447
Profits attributable to a joint venture	<b>(5)</b>	(8)
Income not subject to tax	<b>(8,971)</b>	–
Tax effect of expenses not deductible for tax purposes	<b>98</b>	3,832
Additional deduction allowance for research and development expenses	<b>(25,124)</b>	(33,426)
Tax losses and deductible temporary differences utilised from previous periods	<b>(37)</b>	(77)
Tax effect of tax losses and deductible temporary differences not recognised	<u><b>70,354</b></u>	<u>64,617</u>
Income tax credit recognised in profit or loss	<u><b>(250)</b></u>	<u>(250)</u>

The Group has accumulated unused tax losses of RMB3,803,491,000 available for offset against future profits as of 31 December 2025 (2024: RMB3,537,347,000). The accumulated unused tax loss arising in mainland China or the other regions would expire in one to ten years or indefinitely for offsetting against taxable profits of the companies in which the losses arose. The Group had deductible temporary differences of RMB49,537,000 at 31 December 2025 (2024: RMB41,310,000), which are mainly related to Impairment and accrued expenses.

Deferred taxation have not been recognised in respect of these losses and deductible temporary differences as they have arisen in subsidiaries that have been loss-making for some time and it is not considered probable that taxable profits will be available against which the tax losses and deductible temporary differences can be utilised.

## 7. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY

The calculation of the basic loss per share amounts is based on the loss for the year attributable to ordinary equity holders of the Company, and the weighted average number of ordinary shares of 414,191,329 (2024: 404,790,614) outstanding during the year.

No adjustment has been made to the basic loss per share amounts presented for the years ended 31 December 2025 and 2024 in respect of a dilution as the impact of the share options had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted earnings per share are based on:

	<b>2025</b> <i>RMB'000</i>	2024 <i>RMB'000</i>
<b>Loss</b>		
Loss attributable to ordinary equity holders of the Company for the purpose of calculating basic loss per share	<u><u>(203,725)</u></u>	<u><u>(290,292)</u></u>
<b>Shares</b>		
Weighted average number of ordinary shares for the purpose of calculating basic loss per share*	<u><u>414,191,329</u></u>	<u><u>404,790,614</u></u>

\* The weighted average number of shares for the year shown above has been arrived after deducting the effect of the treasury shares.

## 8. TRADE AND OTHER RECEIVABLES

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Trade receivables	31,851	31,376
Impairment	<u>(15,674)</u>	<u>(13,031)</u>
Net carrying amount	<u><b>16,177</b></u>	<u><b>18,345</b></u>
Prepayments	4,672	7,528
Interest receivables	–	3,949
Other receivables	<u>700</u>	<u>2,014</u>
	5,372	13,491
Impairment allowance	<u>–</u>	<u>(275)</u>
Net carrying amount	<u><b>5,372</b></u>	<u><b>13,216</b></u>
Total	<u><b>21,549</b></u>	<u><b>31,561</b></u>
Analysed into:		
Current portion	21,368	31,107
Non-current portion	181	454

The Group allows a credit period ranging from 30 to 90 days to its customers. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
Within 1 year	1,559	1,187
1 – 2 years	12	11,055
2 – 3 years	8,503	6,103
Above 3 years	<u>6,103</u>	<u>–</u>
	<u><b>16,177</b></u>	<u><b>18,345</b></u>

The movements in the loss allowance for impairment of trade receivables are as follows:

	2025 <i>RMB'000</i>	2024 <i>RMB'000</i>
At beginning of year	13,031	1,200
Impairment losses, net	<u>2,643</u>	<u>11,831</u>
At end of year	<u><b>15,674</b></u>	<u><b>13,031</b></u>

To measure the ECLs, trade receivables have been grouped based on shared credit risk characteristics and the days past due. The ECLs below also incorporate forward-looking information. The impairment is determined as follows:

	<b>2025</b> <i>RMB'000</i>	2024 <i>RMB'000</i>
Expected credit loss rate	<b>49%</b>	42%
Gross carrying amount	<b>31,851</b>	31,376
Impairment	<b>15,674</b>	13,031

## 9. TRADE AND OTHER PAYABLES

	<b>2025</b> <i>RMB'000</i>	2024 <i>RMB'000</i>
Trade payables	<b>67,068</b>	83,143
Accrued research and development expenses	<b>18,591</b>	11,558
Payable for purchase of property, plant and equipment	<b>5,989</b>	10,698
Loans from a related party	<b>2,021</b>	–
Interest payables	<b>95</b>	187
Other tax payables	<b>1,348</b>	1,418
Accrued staff costs and benefits	<b>4,074</b>	4,085
Other payables	<b>7,429</b>	2,840
	<b>106,615</b>	113,929

The average credit period on purchases of goods and services of the Group is 30-90 days. An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	<b>2025</b> <i>RMB'000</i>	2024 <i>RMB'000</i>
Within 30 days	<b>10,970</b>	9,699
31-120 days	<b>6,422</b>	3,367
121-365 days	<b>8,581</b>	34,267
1 – 2 years	<b>24,094</b>	25,876
2 – 3 years	<b>8,306</b>	9,879
Above 3 years	<b>8,695</b>	55
	<b>67,068</b>	83,143

Trade and other payables are unsecured and non-interest-bearing.

## 10. DIVIDENDS

No dividend has been paid or declared by the Company during the year (2024: Nil).

## Other Comprehensive Income/(Loss)

Our other comprehensive income/(loss) increased from the loss of RMB4.0 million in the year ended December 31, 2024 to the income of RMB5.5 million in the year ended December 31, 2025.

## Non-IFRS Measure

To supplement the Group's consolidated financial statements, which are presented in accordance with the IFRS Accounting Standards, the Company also uses adjusted loss and total comprehensive loss for the year and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, the Group's results of operations or financial condition as reported under IFRS. The Company's presentation of such adjusted figure may not be comparable to a similarly titled measure presented by other companies. However, the Company believes that this and other non-IFRS measures are reflections of the Group's normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of the Group's operating performance, and thus facilitate comparisons of operating performance from year to year and company to company to the extent applicable.

Adjusted loss and total comprehensive loss for the period represents the loss and total comprehensive loss for the period excluding the effect of share-based compensation loss. The table below sets forth a reconciliation of the loss and total comprehensive loss to adjusted loss and total comprehensive loss during the periods indicated:

	Year ended December 31,	
	2025	2024
	<i>RMB'000</i>	<i>RMB'000</i>
Total comprehensive loss for the year:	(198,269)	(294,322)
Add:		
Share-based compensation loss	<u>8,262</u>	<u>23,931</u>
Sub-total	<u>8,262</u>	<u>23,931</u>
Adjusted loss and total comprehensive loss for the year	<u><u>(190,007)</u></u>	<u><u>(270,391)</u></u>

## Employees and Remuneration Policies

The following table sets forth a breakdown of our employees as at December 31, 2025 by function:

	Number of employees	% of total number of employees
Research and Development	69	44.51
General and Administrative	40	25.81
Manufacturing	<u>46</u>	<u>29.68</u>
<b>Total</b>	<u><u>155</u></u>	<u><u>100.00</u></u>

The Group believes in the importance of attraction, recruitment and retention of quality employees in achieving the Group's success. Our success depends on our ability to attract, retain and motivate qualified personnel. The number of employees employed by the Group varies from time to time depending on our needs. Employees' remuneration is determined in accordance with prevailing industry practice and employees' educational background, experience and performance. The remuneration policy and package of the Group's employees are periodically reviewed.

Our employee remuneration comprises salaries, bonuses, social security contributions and other welfare payments. In accordance with applicable Chinese laws, we have made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees. The total employee benefit expenses for the twelve months ended December 31, 2025 was RMB16,742,000.

The Company also has one expired share scheme with awards outstanding and one existing share scheme, namely the Pre-IPO Equity Incentive Plan and the Share Incentive Scheme, respectively. Please refer to the section headed "Appendix IV Statutory and General Information – D. Share Schemes" in the prospectus of the Company dated September 14, 2021 (the "**Prospectus**") for further details of the Pre-IPO Equity Incentive Plan and the circular published by the Company on October 16, 2022 for further details of the Share Incentive Scheme.

During the Reporting Period, the Group did not experience any significant labour disputes or any difficulty in recruiting employees.

### **Liquidity and Financial Resources**

On September 29, 2021, 40,330,000 ordinary shares of US\$0.0001 par value each were issued at HK\$16.00 per share for a total gross cash consideration of HK\$645,280,000 (equivalent to RMB536,034,000).

On September 17, 2025, 14,400,000 Placing Shares were issued at the placing price of HK\$4.33 per share for a total gross proceeds of approximately HK\$62.35 million.

As of December 31, 2025, bank balances and cash and pledged/restricted bank deposits were RMB14.4 million, as compared to RMB227.4 million as of December 31, 2024. The decrease was mainly due to the cash outflows of operating activities.

### **Gearing Ratio**

The gearing ratio of the Group was calculated using interest-bearing borrowings less cash and bank balances divided by (deficiency of) total equity and multiplied by 100%. The gearing ratio is 15.11% as at December 31, 2025, as compared to 0.76% as of December 31, 2024.

### **Other Financial Information**

#### **Significant Investments, Material Acquisitions and Disposals**

The Group did not make any significant investments (including any investment in an investee company with a value of five percent or more of the Group's total assets as at December 31, 2025) during the Reporting Period. The Group did not have any material acquisitions or disposals of subsidiaries, associated companies or joint ventures for the year ended December 31, 2025.

## **Foreign Exchange Risk**

The functional currency of the Company is Renminbi. During the Reporting Period, certain bank balances and cash, trade and other receivables, amounts due from related parties, trade and other payables, financial instruments and financial liabilities at fair value through profit or loss are denominated in U.S. dollars, which are exposed to foreign currency risk. The Group currently does not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

## **Bank Loans and Other Borrowings**

As at December 31, 2025, we have no borrowings secured by time deposits.

As at December 31, 2024, borrowings amounting to RMB42,000,000 are secured by pledged bank deposits of RMB50,000,000.

We had an aggregate of RMB91,240,000 overdrafts with fixed interest rates as at December 31, 2025.

## **Contingent Liabilities**

As at December 31, 2025, the Group did not have any material contingent liabilities.

## **Funding and Treasury Policy**

The Group adopts a prudent funding and treasury policy, the management team and the Board monitor and evaluate the financial conditions and liquidity from time to time and on a regular basis, to ensure the Group's assets, liabilities and commitments can meet the funding requirements.

## **Going concern issues and updates on mitigation plans and measures taken in resolving the Disclaimer of Opinion**

### ***Going concern issues***

The independent auditor of the Company, Ernst & Young (the “**Independent Auditor**”), has issued a disclaimer of opinion (“**Disclaimer of Opinion**”) in respect of its audit of the consolidated financial statements for the year ended December 31, 2025 (the “**Consolidated Financial Statements**”), details of which are set out in the sections headed “Basis for Disclaimer of Opinion” and “Disclaimer of Opinion” respectively in the Independent Auditor's Report, and extracted below in the paragraphs headed “Extract of Independent Auditor's Report”.

Since the publication of the Company's annual report for the year ended December 31, 2024 (the “**2024 Annual Report**”), the Group has been undertaking a number of measures and actions, as well as following up on existing ones to mitigate its liquidity pressure and improve its financial position, for which updates on the implementation progress, status and expected outcome were disclosed in the announcements of the Company dated July 11, 2025, 22 October, 2025 and 22 January, 2026 (the “**Progress Updates**”).

### ***The Management’s assessment on the Disclaimer of Opinion***

The management of the Group has given careful consideration to the Disclaimer of Opinion and the basis thereof and has had continuous discussions with the Independent Auditor during the preparation of the Consolidated Financial Statements. The management of the Group understands that the Disclaimer of Opinion relates solely to the validity of going concern assumption, on which the Consolidated Financial Statements have been prepared. The management of the Group has prepared the Group’s cash flow projection, which covers a period of not less than twelve months from December 31, 2025 (the “**Cashflow Projection**”) and has given due consideration to the matters that give rise to material doubt as to its ability to continue as a going concern, and accordingly, has been proactively following through on the plans as disclosed in the 2024 Annual Report and the Progress Updates.

### ***The Directors’ view on the Disclaimer of Opinion***

The Directors, having perused the information prepared by the management, including but not limited to the Cashflow Projection, the Progress Update, and taking into account the management’s report on the latest progress thereto and plans going forward, have (on the basis that such latest plans and measures (as set forth below) are effectively implemented as planned) come to the view that the Group will have sufficient financial resources to finance its operations and meet its financial obligations when they fall due within twelve months from the date of approval of the Consolidated Financial Statements. Accordingly, the Directors have, at the time of approving the Consolidated Financial Statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Save for the matters disclosed herein, the Directors are not aware of any other events or conditions that may cast significant doubt upon the Company’s ability to continue as a going concern, and thus it is appropriate for the Consolidated Financial Statements to be prepared on a going concern basis.

### ***Updates on the latest plans and measures taken or to be taken***

A summary of the latest plans and measures taken or to be taken to support such going concern assumptions, which have been considered, recommended and agreed by the audit committee of the Company (the “**Audit Committee**”) after its critical review of the management’s position for the year ended December 31, 2025 is set forth as follows:

- (i) Engaging with various third parties to further its global development and commercialization of a major pipeline, with “licensing out” and/or “co-development plans”**

The Group continued to advance discussions for the development and commercialization of its lead asset osemitamab with multiple global and regional pharmaceutical companies. Several parties are conducting due-diligence reviews and/or proceeding with term-sheet and contract level negotiations covering global and regional collaboration scopes. The Company has also garnered term-sheet and contract level interest from global and regional investment institutions, with which the Company has been in active discussions to secure funding for the asset. The Company expects to complete negotiations regarding one or more of these term sheets and contracts within the first half of 2026 and initiate the Phase 3 within 2026.

**(ii) Pursuing out-licensing or fund raising to support further development of other pipelines**

The Group continued to be in active discussions with potential partners and investors concerning its other pipeline programs, including among others TST003, TST013, TST198, blosozumab, TST801, TST808 and ozekibart, as part of the Group's broader and ongoing pipeline activities. Progress has been made toward potential global or regional licensing or joint-development arrangements for several of these assets, and multiple parties have been conducting due-diligence reviews. The Group also continued to engage in discussions on the formation of NewCos to attract dedicated external capital to advance selected portfolios.

**(iii) Engaging in discussions and negotiations with various parties for capital fundings**

The Group continued to take a systematic approach to and make progress on diversified financing channels and instruments. Since the last update, the Group has made significant progress with the strategic investment term sheets received. Active negotiations with institutional investors and financial intermediaries are ongoing to further strengthen the Group's balance sheet and fund key R&D programs. Since the last update announcement in January, the Company has engaged with several strategic investors and progressed discussions to the contracting stage with an indicative fundraising target of up to US\$100 million by year-end, subject to market conditions and customary approvals.

**(iv) Exploring non-exclusive, royalty-bearing proprietary technology platform out-licensing opportunities**

On December 29, 2025, the Company announced it had entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a global biopharmaceutical development and manufacturing company, to grant a non-exclusive license to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages. The Company has since received the upfront payment and is eligible to receive further milestone payments, as well as future royalty payments associated with the commercial use of the licensed technologies.

In addition, the Group has been continuing its parallel discussions with other biotechnology and contract manufacturing companies interested in evaluating or licensing its proprietary technology platform including continuous-manufacturing technologies.

**(v) Exploring global partnerships in perfusion and fed batch culture media supply, as well as other co-development and licensing opportunities**

The Group has broadened its collaborations with global and regional cell-culture-media suppliers through multiple material-transfer and evaluation agreements. These initiatives are intended to generate recurring CHO cell culture medium technology license-associated sales revenue streams and deepen strategic relationships within the global supply chain.

**(vi) Negotiating with various banks to renew and extend existing bank borrowings, and secure new bank facilities**

The Group has maintained positive relationships with its banking partners to support the renewal and extension of key loan facilities. The Group continued to make progress in securing additional credit lines to provide continued support for day-to-day operations and R&D expenditures. Discussions with other financial institutions for further financing facilities have also progressed, with a financial leasing secured.

**(vii) Negotiating with suppliers to extend repayment dates of the overdue payables**

The Group has also continued its constructive dialogue with major suppliers. Further payment extensions and revised schedules have been agreed upon, improving short-term cash flow flexibility while ensuring uninterrupted operations.

**(viii) Prospecting and engaging new contract development and manufacturing (CDMO) customers**

The Group's CDMO business continued to gain traction, adding new domestic and potentially international clients across various CDMO service models. This is supported by the Group's integrated capabilities in process development and manufacturing, as well as lead discovery, optimization and clinical development. In particular, continuous bioprocessing is gaining momentum, and more and more companies are exploring continuous bioprocessing for complicated molecules in development. Several new customer contracts are under final negotiation, demonstrating growing market recognition of the Group's integrated development and manufacturing capabilities.

**(ix) Implementing initiatives to align its resources more effectively and efficiently with strategic objectives**

The Group has continued efforts in streamlining its organization and prioritizing investment in programs with the highest partnering and commercial potential. The across-the-board savings in labor, R&D and operating expenses reflect disciplined cost management and enhanced operating efficiency. These actions have meaningfully supported the extension of the Group's cash runway.

***Audit Committee's view on the Disclaimer of Opinion***

The Audit Committee has reviewed the facts and circumstances leading to the Disclaimer of Opinion, discussed with the Auditor and the management of the Company on matters and the basis for the Disclaimer of Opinion, and taken into account the Directors' views thereto and the latest plans and measures undertaken (and continue to focus on) by the Group to support the going concern assumptions used in preparation of the Consolidated Financial Statements. After careful analysis and prudent assessment of the aforementioned plans and measures (if effectively implemented) in mitigating the liquidity burden, optimising the Group's operations and improving its financial position, the Audit Committee concurs with the Directors' assessment and the basis for forming such a view with respect to adopting going concern assumptions in the preparation of the Consolidated Financial Statements.

## ***Extract of Independent Auditor's Report***

The following is an extract from the independent auditor's report:

### *Disclaimer of opinion*

We do not express an opinion on the consolidated financial statements of the Group. Because of the significance of the matters described in the *Basis for disclaimer of opinion* section of our report, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on the consolidated financial statements. In all other respects, in our opinion, the consolidated financial statements have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

### *Basis for disclaimer of opinion*

As set out in note 2.1 to the consolidated financial statements, during the year ended 31 December 2025, the Group incurred a net loss of RMB204 million and a net operating cash outflow of RMB136 million, and as at 31 December 2025, the Group had net current liabilities of RMB160 million. These conditions, together with other matters disclosed in note 2.1 to the consolidated financial statements, cast significant doubt on the Group's ability to continue as going concern.

The directors of the Company have been undertaking a number of plans and measures to improve the Group's liquidity and financial position, which are set out in note 2.1 to the consolidated financial statements. The validity of the going concern assumption on which the consolidated financial statements have been prepared depends on the outcome of these plans and measures, including:

- (i) successfully engaging with various third parties to further its global development and commercialization of a major pipeline, with "licensing-out" and/or "co-development" plans;
- (ii) successfully pursuing out-licensing or fund raising to support further development of other pipelines;
- (iii) successfully engaging in discussions and negotiations with various parties for capital fundings;
- (iv) successfully exploring non-exclusive, royalty-bearing proprietary technology platform out-licensing opportunities;
- (v) successfully exploring global partnerships in perfusion and fed-batch culture media supply, as well as other co-development and licensing opportunities;
- (vi) successfully negotiating with banks to renew and extend existing borrowings, and secure new facilities;

- (vii) successfully negotiating with suppliers to extend repayment dates of overdue payables;
- (viii) successfully prospecting and engaging new contract development and manufacturing customers; and
- (ix) successfully implementing initiatives to align its resources more effectively and efficiently with strategic objectives.

Given the severe financial situation faced by the Group, the execution of the plans and measures by the Group is still in progress and no written contractual agreements or other documentary supporting evidence from the relevant counterparties that are available as at the approval date of the consolidated financial statements, we were unable to obtain sufficient appropriate audit evidence we considered necessary to assess the assumptions underlying the cash flow forecasts and the likelihood of success of the plans and measures currently undertaken by the Group. There were no other satisfactory audit procedures that we could perform to satisfy ourselves with the appropriateness of the directors' use of the going concern basis of accounting and adequacy of the related disclosures in the consolidated financial statements.

Should the Group fail to achieve the abovementioned plans and measures, it might not be able to continue to operate as a going concern, and adjustments would have to be made to write down the carrying amounts of the Group's assets to their realisation amounts, to provide for any further liabilities which might arise and to reclassify non-current assets and non-current liabilities as current assets and current liabilities, respectively. The effects of these adjustments have not been reflected in these consolidated financial statements. The possible effects on the consolidated financial statements of undetected misstatements, if any, could be both material and pervasive.

## **ANNUAL GENERAL MEETING**

The annual general meeting is scheduled to be held on Friday, June 5, 2026 (the "AGM"). A notice convening the AGM will be published and dispatched to the shareholders of the Company (the "Shareholders") in the manner required by the Listing Rules in due course.

## **CLOSURE OF THE REGISTER OF MEMBERS**

The register of members of the Company will be closed from Tuesday, June 2, 2026 to Friday, June 5, 2026, both days inclusive, in order to determine the identity of the Shareholders who are entitled to attend and vote at the AGM, during which period no share transfers will be registered. The record date will be Friday, June 5, 2026. To be eligible to attend and vote at the AGM, unregistered holders of shares must lodge all properly completed transfer forms accompanied by the relevant share certificates with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Monday, June 1, 2026.

## **CORPORATE GOVERNANCE AND OTHER INFORMATION**

The Company was incorporated under the laws of the British Virgin Islands on August 20, 2010 and continued in the Cayman Islands on March 26, 2021 as an exempted company with limited liability, and the Shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on September 29, 2021 (the "Listing Date").

The Company is committed to maintaining and promoting stringent corporate governance. The principle of the Company's corporate governance is to promote effective internal control measures and to enhance the transparency and accountability of the Board to all Shareholders.

The Company has adopted the principles and code provisions set out in the Corporate Governance Code contained in Appendix C1 (as amended from time to time) to the Listing Rules (the "**CG Code**") as the basis of the Company's corporate governance practices.

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for the Group to safeguard the interests of Shareholders and to enhance corporate value and accountability.

### **Compliance with the Corporate Governance Code**

During the Reporting Period, the Company has applied the principles of and complied with all the applicable code provisions set out from time to time in the CG Code, save and except for code provision C.2.1 of Part 2 of the CG Code as explained below.

Code provision C.2.1 of Part 2 of the CG Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. The Company does not have a separate chairman and chief executive officer and Dr. Xueming Qian currently performs these two roles. The Board believes that vesting the roles of both chairman and chief executive officer in the same person has the benefit of ensuring consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. The Board will continue to review and consider splitting the roles of chairman of the Board and the chief executive officer of the Company at a time when it is appropriate by taking into account circumstances of the Group as a whole.

Further information of the corporate governance practice of the Company will be disclosed in the annual report of the Company for the year ended December 31, 2025. The Company will continue to regularly review and monitor its corporate governance practices to ensure compliance with the CG Code, and maintain a high standard of corporate governance practices of the Company.

### **Compliance with the Model Code for Securities Transactions by Directors**

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 (as amended from time to time) to the Listing Rules as its own securities dealing code to regulate all dealings by Directors and relevant employees in securities of the Company and other matters covered by the Model Code.

The provisions under the Listing Rules in relation to compliance with the Model Code by the Directors regarding securities transactions have been applicable to the Company since the Listing Date. Having made specific enquiry, all the Directors have confirmed that they have complied with the Model Code during the Reporting Period.

No incident of non-compliance of the Model Code was noted by the Company during the Reporting Period.

## Purchase, Sale or Redemption of the Company's Listed Securities

During the Reporting Period, the Company repurchased a total of 166,500 ordinary shares (the “**Shares Repurchased**”) of the Company on the Stock Exchange at an aggregate consideration of approximately HK\$99,959.45. The repurchase of shares was conducted to enhance the value in the shares of the Company and for the benefits of the Company and the Shareholders as a whole. Particulars of the Shares Repurchased are as follows:

<b>Month of Repurchase</b>	<b>No. of Shares Repurchased</b>	<b>Repurchase price per share or highest repurchase price per share (HK\$)</b>	<b>Lowest repurchase price per share (HK\$)</b>	<b>Aggregate Consideration (HK\$)</b>
January	166,500	0.6100	0.5800	99,959.45
<b>Total</b>	<b>166,500</b>	<b>–</b>	<b>–</b>	<b>99,959.45</b>

During the Reporting Period, the Shares Repurchased were subsequently reserved as treasury shares.

Save as disclosed above and in the section headed “Other Financial Information”, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company’s securities (including any sale of treasury shares (as defined under the Listing Rules)) listed on the Stock Exchange during the Reporting Period and up to the date of this announcement. As at December 31, 2025, the Company held 2,516,500 treasury shares, which will be used for to transfer or use for share grants under share schemes that comply with Chapter 17 of the Listing Rules, resell at market price to raise additional funds when the Company thinks appropriate, and for other purposes permitted under the Listing Rules, the Articles of Association and the applicable laws of the Cayman Islands, subject to market conditions and our Group’s capital management needs.

### Material Litigation

The Company was not involved in any material litigation or arbitration during the Reporting Period. The Directors are also not aware of any material litigation or claims that were pending or threatened against the Group during the Reporting Period.

### Future Plans for Material Investment or Capital Assets

Save as disclosed in this announcement, the Group does not have other plans for material investments and capital assets as at the date of this announcement.

## USE OF NET PROCEEDS

References are made to the section headed “Future Plans and Use of Proceeds” in the Prospectus, which sets out the Company’s intended use of the net proceeds (the “**Intended Use**”) from the Global Offering of approximately HK\$553.4 million (“**Net Proceeds**”) at the time of the listing of its Shares on the Main Board of the Stock Exchange (the “**Listing**”), the “Change in Use of Net Proceeds” as disclosed in the annual results announcement for the year ended 2022 (the “**2022 Annual Results Announcement**”), the “Further Change in Use of Net Proceeds” as detailed in the interim results announcement for the six months ended June 30, 2024 (the “**2024 Interim Results Announcement**”), the “Latest Change in Use of Net Proceeds” as detailed in the annual results announcement for the year ended 2024 (the “**2024 Annual Results Announcement**”) and the “Updated Change in Use of Net Proceeds” as detailed in the interim results announcement for the six months ended June 30, 2025 (the “**2025 Interim Results Announcement**”) on the reallocation and change in use of Net Proceeds. Unless otherwise defined, capitalized terms used herein shall have the same meaning as those defined in the Prospectus, the 2022 Annual Results Announcement and the 2024 Interim Results Announcement (in the event of conflict or inconsistency, the definitions in the 2024 Interim Results Announcement shall prevail).

As a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development, and manufacturing, we have established a diversified and differentiated pipeline with drug candidates that have first-in-class or best-in-class potential, demonstrate clear clinical benefits, address significantly unmet medical needs and are highly synergistic with other candidates in our pipeline. It is our endeavor to advance our pipelines and edging them closer to commercialization. As disclosed in the section headed “Risk Factors – Risks related to pre-clinical and clinical development of drug candidates” in the Prospectus, clinical trial is expensive and can take a few years to complete, with inherently uncertain outcome. Also disclosed in the Prospectus is the risk of having our limited resources allocated to pursue a particular drug candidate or indication whilst failing to capitalize on drug candidates or indications that may later prove to be more profitable or having a greater likelihood of success. With our business and results of operations hinging on our ability to commercialize our drug candidates, there is thus always the risk that the Intended Use formulated based on predictions, assessment and analysis of the clinical development stages and outcome at the time of the Listing may, at any point in time thereafter, be no longer compatible with our actual operative needs and commercialization goals.

In view of the accelerated development post-Listing of our leading assets including but not limited to osemitamab (TST001), a potential best-in-class and differentiated antibody targeting Claudin18.2, a validated tumor associated antigen, which has gradually emerged as having the highest potential of commercialization, the Board has, after re-evaluating the Intended Use, resolved to reallocate the respective amounts of approximately HK\$166 million, HK\$30.0 million and HK\$50.8 million of the unutilized Net Proceeds to fund the development of osemitamab (TST001), details of such Change in Use of Net Proceeds, Further Change in Use of Net Proceeds, Latest Change in Use of Net Proceeds and Updated Change in Use of Net Proceeds, as well as the reasons therefor are disclosed in the 2022 Annual Results Announcement, the 2024 Interim Results Announcement, the 2024 Annual Results Announcement and the 2025 Interim Results Announcement. Such reallocation and deployment of unutilized Net Proceeds is considered to be more in line with our current business needs and our aim to develop osemitamab (TST001) as the global cornerstone treatment in Claudin18.2 expressing solid tumors including G/GEJ cancer, PDAC, and lung cancer, as well as enhance our Claudin18.2 franchise through proprietary combinations of osemitamab (TST001) with our other key oncology drug candidates.

Further to the aforementioned strategic realignment of resources and to accord priority to pressing project needs, the Board has resolved to further change the Intended Use on August 27, 2025, by reallocating HK\$28.8 million from the unutilized Net Proceeds previously applied towards the development of TST005, TST002 and business development to fund the development of osemitamab (TST001) and other projects that currently require support and funding to progress further, especially for pipeline products that require funding for pre-clinical trials and registration filings. The table below sets out the utilization of Net Proceeds as at December 31, 2025, the allocation of the remaining unutilized Net Proceeds and the expected timeline for utilization of the remaining unutilized Net Proceeds:

Use of Net Proceeds	Amount of	Amount of	Amount	Allocation of	Intended	Expected
	utilized	unutilized		Net Proceeds	allocation of	
	Net Proceeds	Net Proceeds	utilized during	the Updated	the remaining	timeline of
	as at	as at	the Reporting	Change in	Net Proceeds	full utilization
	December 31,	December 31,	Period	Use of	the Updated	of the unutilized
	2025 <sup>1</sup>	2025 <sup>1</sup>		Net Proceeds	Change in	Net Proceeds
	HK\$ million	HK\$ million	HK\$ million	HK\$ million	Use of	Net Proceeds
					Net Proceeds	Net Proceeds
					% of remaining	Net Proceeds
					unutilized	Net Proceeds
					Net Proceeds	Net Proceeds
					(approximately)	Net Proceeds
1. Research and development of our pipeline product candidates, funding of ongoing and planned clinical and pre-clinical trials, preparation for registration filings and other steps or activities related to the commercialization of our four anchor products as follows:	498.1	-	30.8	498.1	-	On or before December 31, 2025
(i) fund ongoing and planned clinical trials, preparation for registration filings and potential commercial launch (including sales and marketing) of our key product, osemitamab (TST001)	375.1	-	25.6	375.1	-	On or before December 31, 2025
(ii) fund ongoing and planned clinical trials, preparation for registration filings and potential commercial launch (including sales and marketing) of our key product, TST005	14.3	-	2.0	14.3	-	On or before December 31, 2025
(iii) fund ongoing and planned clinical trials, preparation for registration filings and potential commercial launch (including sales and marketing) of our key product, TST002	31.1	-	-	31.1	-	On or before December 31, 2025

Use of Net Proceeds	Amount of	Amount of	Amount	Allocation of	Intended	Expected
	utilized	unutilized		Net Proceeds	allocation of	
	Net Proceeds	Net Proceeds	utilized during	the Updated	the remaining	timeline of
	as at	as at	the Reporting	Change in	Net Proceeds	of the unutilized
	December 31,	December 31,	Period	Use of	the Updated	Net Proceeds
	2025 <sup>1</sup>	2025 <sup>1</sup>	HK\$ million	Net Proceeds	Change in	of the unutilized
	HK\$ million	HK\$ million	HK\$ million	HK\$ million	Use of	Net Proceeds
					Net Proceeds	of the unutilized
					(approximately)	Net Proceeds
(iv) fund ongoing and planned pre-clinical trials and preparation for registration filings of our key product and other pipeline products, including TST004, MSB0254, TST003, TST006 and TST008	77.6	-	3.2	77.6	-	On or before December 31, 2025
2. Fund the business development for pipeline expansion and technology development, with a focus in oncology assets that have synergy with our current pipeline and promising clinical evidences, and/or technology platforms that can complement our current discovery and development platforms, such as ADC, small molecule targeted therapies, and other advanced new technologies	-	-	-	-	-	On or before December 31, 2025
3. For general working capital purposes and general operation expenses	55.3	-	-	55.3	-	On or before December 31, 2025
<b>Total</b>	<b>553.4</b>	<b>-</b>	<b>30.8</b>	<b>553.4</b>	<b>-</b>	

*Note:*

- The amount of utilized and unutilized Net Proceeds before the Updated Change in Use of Net Proceeds.

During the Reporting Period, the Company also completed a placing of new Shares, which generated gross proceeds of approximately HK\$62.35 million and net proceeds of approximately HK\$59.34 million after deducting placing commissions and other related expenses. As at December 31, 2025, approximately HK\$34.84 million of the net proceeds from the placing had been utilized for (i) the clinical development of the Group's pipeline assets, including TST001 and TST002, and (ii) the advancement of pre-clinical-stage pipeline assets with near-term out-licensing potential, including TST801, TST013 and TST786, and approximately HK\$17.8 million had been applied towards working capital and general corporate purposes, including general business operations and business development.

The unutilized net proceeds from the placing as at December 31, 2025 amounted to approximately HK\$6.7 million and are expected to be fully utilized on or before December 31, 2026, in accordance with the intended use as disclosed in the announcement of the Company dated 10 September 2025. The Board confirms that there has been no material change in the intended use of proceeds from the placing as previously disclosed. The Company intends to apply the net proceeds from the placing as follows:

Use of net proceeds from the Subscription	% of net proceeds	Net proceeds from the Subscription	Amount utilized as at December 31, 2025	Amount of unutilized net proceeds as at December 31, 2025	Expected timeline of full utilization
Clinical development of pipeline assets, including TST001 and TST002	40%	HK\$23.74 million	HK\$23.74 million	HK\$0 million	On or before December 31, 2026
Advancement of pre-clinical-stage pipeline assets with near-term out-licensing potential, including TST801, TST013 and TST786	30%	HK\$17.80 million	HK\$11.1 million	HK\$6.7 million	On or before December 31, 2026
Working capital and general corporate purposes, including general business operations and business development	30%	HK\$17.80 million	HK\$17.8 million	HK\$0 million	On or before December 31, 2026
<b>Total</b>	<b>100%</b>	<b>HK\$59.34 million</b>	<b>HK\$52.64 million</b>	<b>HK\$6.7 million</b>	

### Audit Committee

The Company has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the CG Code. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal controls system of our Group, review and approve connected transaction (if any) and provide advice and comments to the Board. The Audit Committee comprises three members, namely Mr. Jiasong Tang (唐稼松), Mr. Zhihua Zhang (張志華) and Dr. Li Xu (徐莉), with Mr. Jiasong Tang (唐稼松) (being our independent non-executive Director with the appropriate professional qualifications) as chairperson of the Audit Committee.

The Audit Committee has reviewed the audited consolidated financial statements of the Group for the year ended December 31, 2025 and has met with the Auditor, and reviewed the consolidated financial statements of the Group for the year ended December 31, 2025 in conjunction with the Auditor. The Audit Committee has also discussed matters with respect to the accounting policies and practices adopted by the Company, internal control and financial reporting matters with senior management members of the Group. The Audit Committee considers that this announcement is in compliance with the relevant accounting standards, rules and regulations and appropriate disclosures have been duly made.

### Other Board Committees

In addition to the Audit Committee, the Company has also established a nomination committee and a remuneration committee.

## **Scope of work of Ernst & Young**

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2025 as set out in this announcement have been agreed by Auditor, to the amounts set out in the Group's audited consolidated financial statements for the year ended December 31, 2025. The work performed by the Auditor in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no assurance has been expressed by the Auditor on this announcement.

## **FINAL DIVIDEND**

The Board does not recommend the distribution of a final dividend for the year ended December 31, 2025.

## **PUBLICATION OF THE ANNUAL RESULTS ANNOUNCEMENT AND ANNUAL REPORT**

This annual results announcement is published on the websites of the Stock Exchange (<http://www.hkexnews.hk>) and the Company (<http://www.transcenta.com/>).

The annual report of the Group for the year ended December 31, 2025 will be published on the aforesaid websites of the Stock Exchange and the Company and will be dispatched to the Shareholders who have already provided instructions indicating their preference to receive hard copies in due course.

## **APPRECIATION**

The Board would like to express its sincere gratitude to the Shareholders, management team, employees, business partners and customers of the Group for their support and contribution to the Group.

By order of the Board  
**Transcenta Holding Limited**  
**Xueming Qian**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, March 31, 2026

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director, chairman and chief executive officer, Dr. Li Xu as non-executive Director, and Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan and Ms. Helen Wei Chen as independent non-executive Directors.*